Jay M. Lee

Present Title & Affiliation

• Surgical Director, Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, UCLA
• Associate Professor of Surgery, David Geffen School of Medicine, UCLA
• Division of Thoracic Surgery, UCLA Health, Los Angeles, CA, USA

Committee Service

Local (UCLA):

• Interviewer, General & Cardiothoracic Surgery Residency Programs (since 2006)
• Executive Committee, Department of Surgery (2013–2022)
• UCLA Health System Quality Council; Quality Measurement & Improvement Committee (since 2013)
• Clinical Competence Committee, UCLA Santa Monica / Thoracic Surgery Task Force (2013–2022)
• Department of Surgery Ad Hoc Bylaws Committee (2013–2014)
• Clinical Excellence Committee, UCLA (since 2014)
• ValU-Based Care Redesign and Faculty Practice Group Quality Committee (2014–2015)
• Endocrine Surgery Faculty Search Committee (2015–2016)
• Internal Advisory Board, UCLA–Boston University EDRN (2015–2016)
• UCLA Health Advisory Board (since 2022)

National & International:

• Basic and Translational Science Committee, ACOSOG (2011–2013)
• Examiner, American Board of Thoracic Surgery (ABTS) – General Thoracic Consultant Subcommittee (2011–2015)
• Examiner, ABTS Oral Board Exam (2013–2015)
• Chair, Video Committee (General Thoracic Section), American Association for Thoracic Surgery (AATS) (2015–2017)
• Steering Committee Member / Chair – multiple Phase II–III Lung Cancer Trials (LCMC3, NAUTIKA1, CANOPY-N, GEOMETRY-N, NeoKAN, INTerpath-002, TROFUSE-019, Skyscraper-15, HORIZON-2, SUNRAY-02, Beamion LUNG)
• Education & Scientific Program Committee Member – AATS, ASCO, IASLC, ESTS (2017–2025)

Professional and Scholarly Associations

• American College of Surgeons (FACS) – since 1998
• American Association for Thoracic Surgery (AATS) – since 2013
• Society of Thoracic Surgeons (STS) – since 2010
• International Association for the Study of Lung Cancer (IASLC) – since 2007
• American Society of Clinical Oncology (ASCO) – since 2017
• European Society for Medical Oncology (ESMO) – since 2021
• European Society of Thoracic Surgeons (ESTS) – since 2021
• American Association for Cancer Research (AACR) – since 2010
• International Mesothelioma Interest Group (iMig), International Thymic Malignancy Interest Group (ITMIG), and General Thoracic Surgical Club (GTSC)
• Society of University Surgeons (SUS)
• Tumor Microenvironment (TME) & Cancer Immunology (CIMM) Working Groups

Editorial Activities

Reviewer for:

• American Journal of Transplantation
•  American Journal of Surgery
• Annals of Surgical Oncology
• Annals of Thoracic Surgery
• Journal of Thoracic & Cardiovascular Surgery
•  Journal of Surgical Oncology
•  Journal of Cancer Research & Clinical Oncology
•  Expert Review of Respiratory Medicine

Editorial Board:

• American Journal of Translational Research (since 2010)
• Lung Cancer Management (since 2011)
• Journal of Visualized Surgery (2015–2018)
• Clinics in Surgery (since 2016)
• Journal of Thoracic Disease (since 2016)
• Current Challenges in Thoracic Surgery (since 2019)
• Frontiers in Oncology – Associate Editor, Thoracic Oncology (since 2022)

Teaching Activities (UCLA)

• Chair, Thoracic Surgery Journal Club (2006–2008)
• Chair, Thoracic Oncology Program Tumor Board (since 2006)
• Lecturer, Thoracic Surgery Teaching Rounds and Core Curriculum Series (since 2006)
• Proctor, Intern Skills Lab, Department of Surgery (since 2006)
• Faculty, Biomedical Physics 227: Human Disease and Biomedical Physics
• Lecturer, Thoracic Surgical Curriculum (Society of Thoracic Surgeons)

Investigator-Initiated Clinical Trials

1. FDA Investigational New Drug (IND) Applications – Approved
   IND 13289: A Phase I Trial of CCL21 Gene-Modified Dendritic Cells in Non-Small Cell Lung Cancer
   Principal Investigator: Jay M. Lee, MD
2. IND 112350: Evaluation of Apricoxib (selective COX-2 inhibitor) in Modulating T-Regulatory Cells of Patients with Early-Stage NSCLC
   Principal Investigator: Jay M. Lee, MD

Lectures and Presentations

1. “HDL inhibits Oxidized LDL–induced Macrophage Proliferation.” Atherosclerosis Research Conference, UCLA Medical Center, Los Angeles, CA. August 1995.

2. “Surgical Management of Gastroesophageal Reflux Disease.” Grand Rounds, Department of Surgery, Georgetown University Medical Center, Washington, DC. November 1998.

3. “Dendritic Cell Modification Ex Vivo by Adenovirus Gene Transfer: Evaluation of Anti-tumor Efficacy In Vivo.”Chairman’s Research Conference, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. June 2000.

4. “In Vivo Transfer of the Macrophage-Derived Chemokine Gene to Established Tumors Inhibits Their Growth and Induces a Cytotoxic T-Lymphocyte Response.” Visiting Professor Conference (Avers, B.M., MD), Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. December 2000.

5. “Adenovirus-Mediated Gene Transfer of the Truncated p65 NF-κB cDNA to Dendritic Cells and Evaluation of its Anti-tumor Efficacy.” Visiting Professor Conference (Niederhuber, J., MD), Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. January 2001.

6. “Adenovirus-Mediated Gene Transfer of the Truncated p65 NF-κB cDNA to Dendritic Cells and Evaluation of its Anti-tumor Efficacy.” Visiting Professor Conference (Niederhuber, J., MD), Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. January 2001.

7. “Intratumoral Administration of Dendritic Cells Genetically Modified to Express the Truncated p65 Form of NF-κB Induces Regression of Established Tumors.” Visiting Professor Conference (Van de Velde, C., MD), Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. May 2001.

8. “Current Management of Retroperitoneal Sarcomas.” Regional Rounds, Department of Surgery, Duke University Medical Center, Durham, NC. March 2002.

9. “Update on Gallbladder Carcinoma.” Regional Rounds, Department of Surgery, Duke University Medical Center, Durham, NC. April 2002.

10. “Neoadjuvant Chemoradiation for Esophageal Cancer.” Regional Rounds, Department of Surgery, Duke University Medical Center, Durham, NC. September 2002.

11. “Surgical Treatment of Stanford Type B (Descending) Aortic Dissections.” Grand Rounds, Department of Surgery, Duke University Medical Center, Durham, NC. April 2003.

12. “Current Status of Carotid Angioplasty and Stenting.” Vascular Multidisciplinary Conference, Department of Surgery, Duke University Medical Center, Durham, NC. September 2003.

13. “Gene Therapy for Lung Cancer.” Grand Rounds, Department of Surgery, Duke University Medical Center, Durham, NC. June 2004.

14. “Update on Mesothelioma.” Harvard Combined Cardiothoracic Surgery Conference, Brigham and Women’s Hospital, Boston, MA. November 2004.

15. “Atypical Pulmonary Infections.” Grand Rounds, Divisions of Cardiac & Thoracic Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA. January 2005.

16. “Tracheal Resection in Lung Cancer.” Harvard Combined Cardiothoracic Surgery Conference, Beth Israel Deaconess Hospital, Boston, MA. March 2005.

17. “Current Status in Thymoma Classifications.” Harvard Combined Cardiothoracic Surgery Conference, Children’s Hospital Boston, Boston, MA. May 2005.

18. “Surgical Management of T3 and T4 NSCLC.” Thoracic Tumor Board Lecture Series, UCLA Medical Center, Los Angeles, CA. October 13, 2006.

19. “Mediastinal Re-staging in Stage IIIA (N2) NSCLC after Induction Therapy.” Thoracic Oncology Program Tumor Board, UCLA Medical Center, Los Angeles, CA. April 20, 2007.

20. “Clinical Update on Non-Small Cell Lung Cancer.” San Gabriel Valley Medical Center Cancer Symposium, San Gabriel, CA. April 29, 2007.

21. “Understanding Stage 3A NSCLC.” UCLA Clinical Update: Advances in Pancreatic, Lung, and Esophageal Disorders, Monterey Park, CA. October 18, 2007.

22. “Transcriptional Repressor SNAIL Promotes Metastasis and Angiogenesis in Human Non-Small Cell Lung Cancer.”Longmire Surgical Society, David Geffen School of Medicine at UCLA, Los Angeles, CA. March 28, 2008.

23. “Clinical Decision-Making in Non-Small Cell Lung Cancer.” Core Curriculum Series, Division of Pulmonary Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. May 1, 2008.

24. “Simulators in Surgical Education.” Science of Thoracic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. October 4, 2008.

25. “A Phase I Trial of CCL21 Gene-Modified Dendritic Cells in NSCLC.” STOP Cancer 17th Annual Research Awards Evening, Four Seasons Hotel, Beverly Hills, CA. October 7, 2008.

26. “Lung Cancer 2008: Traditional and Novel Approaches.” Insights into Cancer Lecture, Simms/Mann UCLA Center for Integrative Oncology, Los Angeles, CA. December 2, 2008.

27. “Mediastinal Staging in Non-Small Cell Lung Cancer.” 6th Annual UCLA Update on Pulmonary Medicine and Critical Care, Santa Monica, CA. February 28, 2009.

28. “Mediastinal Staging in Non-Small Cell Lung Cancer.” Core Curriculum Series, Division of Pulmonary Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. July 2, 2009.

29. “Gene-Modified Dendritic Cell Therapy for Lung Cancer.” UCLA Gene Therapy Interest Group Meeting, Los Angeles, CA. December 14, 2009.

30. “Advances in Lung Cancer Conference 2010.” International Association for the Study of Lung Cancer (IASLC), 10th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA. February 24, 2010.

31. “Gene-Modified Dendritic Cell Therapy for Lung Cancer.” General Thoracic Biology Club, 90th Annual Meeting of the American Association for Thoracic Surgery (AATS), Toronto, Canada. May 1, 2010.

32. “Heartburn, GERD, and Barrett’s Esophagus: Surgery and the Esophagus – What Does Minimally Invasive Mean?”Community Education Program, UCLA Center for Esophageal Disorders, Los Angeles, CA. July 28, 2012.

33. “Phase I Trial of Gene-Modified Dendritic Cell Immunotherapy for Human Lung Cancer.” 169th Meeting of the Society of Clinical Surgery (SCS), Los Angeles, CA. November 2, 2012.

34. “What’s New in Lung Cancer?” UCLA Primary Care Update 2014, Las Vegas, NV. April 4, 2014.

35. “Immune Response in a Phase I Trial of Transthoracic CCL21 Gene-Modified Dendritic Cell Immunotherapy for Human Lung Cancer is Associated with PD-L1 Expression.” 18th Annual UCLA Human Gene Medicine Program Symposium – Immunotherapy, Los Angeles, CA. September 29, 2014.

36. “Phase I Trial of Intratumoral CCL21 Gene-Modified Dendritic Cells.” 15th Annual Targeted Therapies of Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA. February 19, 2015.

37. “Pulmonary Metastasectomy: Ablate, Radiate, or Resect — What is the Evidence?” Postgraduate Course, American Association for Thoracic Surgery (AATS) 96th Annual Meeting, Baltimore, MD. May 15, 2016.

38. “Pulmonary Nodule Localization – Best Method.” Focus on Thoracic Surgery: Mastering Surgical Innovation 2017, American Association for Thoracic Surgery (AATS), Las Vegas, NV. October 27, 2017.

39. “Role of Immunotherapy – Checkpoint Inhibitors.” Focus on Thoracic Surgery: Mastering Surgical Innovation 2017, American Association for Thoracic Surgery (AATS), Las Vegas, NV. October 28, 2017.

40. “Neoadjuvant Immuno-Oncology for NSCLC.” 18th Annual Targeted Therapies Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA. February 22, 2018.

41. “Neoadjuvant Immuno-Oncology for NSCLC.” Lung Cancer Immunotherapy Meeting, International Association for the Study of Lung Cancer (IASLC), Madrid, Spain. March 24, 2018.

42. “How Are Genomics Relevant to the Practicing Lung Cancer Surgeon.” Clinical Congress 2018, American College of Surgeons (ACS), Boston, MA. October 22, 2018.

43. “Neoadjuvant Atezolizumab (LCMC3) and Pembrolizumab.” 19th Annual Targeted Therapies Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA. February 22, 2019.

44. “What the Thoracic Surgeon Needs to Know About Checkpoint Inhibition.” Roundtable Discussion, American Association for Thoracic Surgery (AATS) 99th Annual Meeting, Toronto, Canada. May 5, 2019.

45. “Is Neoadjuvant or Adjuvant Immunotherapy in Our Future for Resected NSCLC?” Education Session, 2019 Annual Meeting, American Society of Clinical Oncology (ASCO), Chicago, IL. June 3, 2019.

46. “Extrapleural Pneumonectomy vs. No Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma.” 2019 Mesothelioma Meeting, International Association for the Study of Lung Cancer (IASLC), New York, NY. July 11, 2019.

47. “Neoadjuvant Pembrolizumab in Resectable Malignant Pleural Mesothelioma.” 2019 Mesothelioma Meeting, International Association for the Study of Lung Cancer (IASLC), New York, NY. July 11, 2019.

48. “Is Neoadjuvant or Adjuvant Immunotherapy in Our Future for Resectable NSCLC?” UCLA Surgery Grand Rounds, Los Angeles, CA. July 17, 2019.

49. “Localization Techniques for Subsolid Nodules.” MyTube: Pushing the Limits of Minimally Invasive Thoracic Surgery and Avoiding Pitfalls, 56th Annual Meeting of the Society of Thoracic Surgeons (STS), New Orleans, LA. January 26, 2020.

50. “Canakinumab in Surgically Resectable Non-Small Cell Lung Cancer.” 20th Annual Targeted Therapies Lung Cancer Meeting, International Association for the Study of Lung Cancer (IASLC), Santa Monica, CA. February 21, 2020.

51. “Immunotherapy (IO) in Stage III NSCLC.” European Lung Cancer Congress (ELCC), European Society for Medical Oncology (ESMO), Virtual. March 25–27, 2021.

52. “Neoadjuvant Treatment (Immunotherapy and Targeted Therapy) Options in Early-Stage Non-Small Cell Lung Cancer.” Keynote Speaker, Thoracic Oncology of Australasia Group (TOGA) Annual Scientific Meeting, Sydney, Australia. July 22–23, 2021.

53. “Thoracic Surgery in Locally Advanced NSCLC.” Keynote Speaker, 6th Annual Middle East and Africa Oncology Summit, Virtual (Egypt). October 21 & 23, 2021.

54. “Updates on Lung Cancer Surgery: Thoracic Surgical Oncologic Perspective.” Invited Speaker, Society of Interventional Oncology Annual Scientific Meeting, San Francisco, CA. March 24–28, 2022.

55. “Integration of New Adjuvant Therapies into Clinical Practice for Resectable NSCLC: What is the Role of the Surgeon.” Keynote Speaker, Einstein International Congress on Robotic Thoracic Surgery, Albert Einstein Israeli Institute for Education and Research, São Paulo, Brazil. June 17, 2022.

56. “IMpower010: Adjuvant Atezolizumab in Resectable NSCLC.” Invited Speaker, 48th Annual Meeting of the Western Thoracic Surgical Association, Koloa, HI, USA. June 24, 2022.

57. “Neoadjuvant, Adjuvant, and Perioperative Clinical Trials.” Grand Rounds Speaker, UCLA Department of Surgery, Los Angeles, CA. September 28, 2022.

58. “IMpower010: Adjuvant Atezolizumab in Resectable NSCLC.” Invited Speaker, American Association for Thoracic Surgery (AATS) / International Thoracic Surgical Oncology Summit, New York, NY. September 20, 2022.

59. “ADAURA: Adjuvant Osimertinib in EGFR-Mutant NSCLC.” Invited Speaker, DAVA Oncology’s Best Practices in Lung Cancer Meeting, Virtual. October 19, 2022.

60. “Targeted Oncology: Lung Cancer Case-Based Roundtable Panel Discussion.” Invited Speaker, Virtual. November 22, 2022.

61. “Clinical Consideration and Management of Atezolizumab as Adjuvant Therapy in Resectable NSCLC.” Keynote Speaker, Taiwan Thoracic Surgery Association Winter Meeting / Taiwan Thoracic and Intensive Care Medicine Annual Joint Symposium, Kaohsiung City, Taiwan. December 10, 2022.

62. “Chest Wall Tumors Approach.” Invited International Speaker, 1st Iberic Thoracic Surgery Meeting / SPCCTV 4D Visions Conference 2022, Portuguese Society of Cardiac, Thoracic and Vascular Surgery & Portuguese Society of Anesthesiology, Albufeira, Portugal. November 26, 2022.

63. “Update on Lung Cancer Screening.” Invited Speaker, Annual Meeting of the Society of Thoracic Surgeons (STS), San Diego, CA. January 23, 2023.

64. “Update on Adjuvant Therapy for EGFR-Mutant NSCLC.” Invited Speaker, DAVA Oncology’s Best Practices in Lung Cancer Meeting, Virtual. February 15, 2023.

65. “Update on Adjuvant Therapy for EGFR-Mutant NSCLC.” Invited Speaker, DAVA Oncology’s Best Practices in Lung Cancer Meeting, Virtual. April 5, 2023.

66. “Optimizing Treatment Plans in Patients with Resectable NSCLC.” Invited Speaker, 103rd Annual Meeting of the American Association for Thoracic Surgery (AATS), Los Angeles, CA. May 6, 2023.

67. “CheckMate 816: Neoadjuvant Chemotherapy and Nivolumab in Resectable NSCLC.” Invited Speaker, 103rd Annual Meeting of the American Association for Thoracic Surgery (AATS), Los Angeles, CA. May 7, 2023.

68. “Immunotherapy for Locally Advanced Lung Cancer: Give It on the Back End.” Invited Speaker, State of the Art: Immunotherapy for Thoracic Malignancies Session, 103rd Annual Meeting of the American Association for Thoracic Surgery (AATS), Los Angeles, CA. May 8, 2023.

69. “How Can Multidisciplinary Approach and Precision Medicine/Biomarker Testing Improve Patients’ Early Lung Cancer Journey?” Invited International Speaker, Paradigm Shift in the Management and Treatment of Early NSCLC Patients, Israeli Society of Clinical Oncology and Radiation Therapy, Israel. May 15, 2023.

70. “Grand Rounds in Thoracic Surgery.” Invited International Speaker, Royal Brompton Hospital, London, United Kingdom (Virtual). August 4, 2023.

71. “Real-world biomarker testing and treatment patterns in resectable non-small cell lung carcinoma.” Invited Speaker, 2023 World Conference on Lung Cancer (WCLC), International Association for the Study of Lung Cancer (IASLC), Singapore. September 11, 2023.

72. “Updated CheckMate 816 three-year data with surgical outcomes.” Invited Speaker, Annual CHEST Meeting 2023, American College of Chest Physicians, Honolulu, HI, USA. October 11, 2023.

73. “Current results of perioperative adjuvant therapies based on global trials: overview and perspective.” Invited International Speaker, The Forefront of Perioperative Therapeutic Development for Lung Cancer – Japan’s Position and Challenges in the World, 64th Annual Japan Lung Cancer Society, Chiba, Japan. November 2, 2023.

74. “Best surgical approaches for stage III NSCLC.” Invited Speaker, MaTOS Masters in Thoracic Oncology Summit, Santa Ana Pueblo, NM, USA. November 16–18, 2023.

75. “Importance of the pulmonologist in the multidisciplinary team in the era of biomarker and molecular testing for resectable non-small cell lung cancer.” Invited Speaker, Pulmonary Grand Rounds, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. December 11, 2023.

76. “Perioperative immunotherapy in resectable non-small cell lung cancer: update and perspective.” Invited Speaker, Thoracic Oncology Lecture, Dana-Farber Cancer Institute, Boston, MA, USA. December 12, 2023.

77. “Neoadjuvant, perioperative, and adjuvant immunotherapies in resectable non-small cell lung cancer: how do we choose?” David J. Sugarbaker Visiting Professor, Grand Rounds, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. December 13, 2023.

78. “Neoadjuvant immunotherapy and chemotherapy for early-stage NSCLC – surgeon’s perspectives.” Invited International Speaker, Taiwan Association for the Study of Lung Cancer (TASLC) 2024 TASLC International Symposium on Treatment Advances in Lung Cancer, Taipei, Taiwan. January 13–14, 2024.

79. “Neoadjuvant immunotherapy and chemotherapy for stage II and III non-small cell lung cancer.” Keynote Speaker, 2024 Prof. Yung-Chie Lee Memorial Symposium, Taiwan Society of Thoracic Surgeons Meeting, National Taiwan University Cancer Center, Taipei, Taiwan. January 14, 2024.

80. “Current immunotherapy data in early-stage resectable lung cancer disease.” Invited International Speaker, MSD China 5th iMAX-MSD Oncology Summit Forum, Shanghai, China. February 3, 2024.

81. “Current immunotherapy data in early-stage resectable lung cancer disease.” Invited International Speaker, MSD China 5th iMAX-MSD Oncology Summit Forum, Beijing, China. February 4, 2024.

82. “NSCLC IO experiences sharing.” Invited International Speaker, MSD China 5th iMAX-MSD Oncology Summit Forum, Beijing, China. February 5, 2024.

83. “Neoadjuvant, perioperative, and adjuvant therapies for resectable non-small cell lung cancer: lessons learned and unmet needs.” Beck Visiting Professor, Department of Surgery, University Hospitals, Case Western University, Cleveland, OH, USA. February 28, 2024.

84. “Neoadjuvant, perioperative, and adjuvant immunotherapy (IO) for resectable non-small cell lung cancer: understanding the rationale for adjuvant IO.” Keynote Speaker, Investigator’s Meeting: Phase 3 Adjuvant V940-002 (INTerPath-002) Trial, Houston, TX, USA. March 12, 2024.

85. “Neoadjuvant, perioperative, and adjuvant immunotherapy (IO) for resectable non-small cell lung cancer: superiority of the perioperative approach.” Keynote Speaker, Investigator’s Meeting: Phase 3 Perioperative MK2870-019 Trial, Chicago, IL, USA. March 15, 2024.

86. “Perioperative strategies in NSCLC.” Speaker, OncLive State of the Science Summit: Lung Cancer, Beverly Hills, CA, USA. June 11, 2024.

87. “Current trials of neoadjuvant targeted therapy in NSCLC (ALK, RET, EGFR, NTRK, ROS1, etc.).” Invited Speaker, 3rd Global Summit on Thoracic Malignancies, DAVA Oncology, Kona, HI, USA. June 25–29, 2024.

88. “Adjuvant mRNA vaccine therapy and PD-1-targeted checkpoint therapy in NSCLC.” Invited Speaker, 3rd Global Summit on Thoracic Malignancies, DAVA Oncology, Kona, HI, USA. June 25–29, 2024.

89. “Role of immunotherapy in early-stage NSCLC: surgeon’s perspective.” Invited International Speaker, Integrated Management of Early-Stage NSCLC: A Multidisciplinary Forum 2024, Singapore Society of Oncology and MSD, Singapore. July 5, 2024.

90. “Cutting-edge treatment strategies for early-stage cancers: improving patient outcomes.” Invited International Speaker, 27th National Congress of Clinical Oncology / Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and MSD China, Xiamen, China. September 25, 2024.

91. “Alectinib – new indication based on results from the Phase III ALINA study.” Invited Speaker, Genentech / American Association for Thoracic Surgery (AATS) / International Thoracic Surgical Oncology Summit (ITSOS), New York, NY, USA. September 27, 2024.

92. “Reinforcing precision tactics in genomically altered resectable NSCLC: strategies for developing collaborative workflows and personalized solutions for optimal integration of adjuvant EGFR- and ALK-targeted therapies.” Invited Speaker, PeerView / AATS / International Thoracic Surgical Oncology Summit (ITSOS), New York, NY, USA. September 27, 2024.

93. “Is there a role for adjuvant therapy after neoadjuvant immunotherapy?” Invited Speaker, Great Debates & Updates in Lung Cancer 2024, Dallas, TX, USA. October 6, 2024.

94. “Evolving role of surgery in the era of immunotherapy and targeted therapy in resectable NSCLC.” Invited Speaker, Barbara Ann Karmanos Cancer Center Lung Cancer Symposium, Detroit, MI, USA. October 19, 2024.

95. “Perioperative chemo/immunotherapy and surgical outcomes.” Invited Speaker, MaTOS Masters in Thoracic Oncology Summit, Truckee, CA, USA. November 21–24, 2024.

96. “Neoadjuvant, perioperative, and adjuvant immunotherapy (IO) for resectable NSCLC: superiority of the perioperative approach.” Keynote Speaker, Investigator’s Meeting: Phase 3 Perioperative V940-009 (INTerPath-009) Trial, San Diego, CA, USA. January 15, 2025.

97. “Current landscape and future directions of perioperative immunotherapy in NSCLC.” Invited International Speaker, MSD China 6th iMAX-MSD Oncology Summit Forum – Pan-Tumor Session, Beijing, China. January 18, 2025.

98. “Unmet treatment needs of perioperative immunotherapy in early-stage NSCLC.” Invited International Speaker, MSD China 6th iMAX-MSD Oncology Summit Forum – Lung Cancer Session, Beijing, China. January 18, 2025.

99. “Unmet treatment needs of perioperative immunotherapy in early-stage NSCLC.” Invited International Speaker, MSD China / CSCO Immunotherapy Express Conference, Shanghai, China. January 19, 2025.

100. “Multidisciplinary team collaboration and research directions on immunotherapy for early-stage NSCLC.” Invited International Speaker, Shanghai Chest Hospital, Shanghai, China. January 20, 2025.

101. “Perceptions on treatment mode (neoadjuvant, adjuvant, and perioperative) of immunotherapy in resectable NSCLC.” Invited International Speaker, Fudan University Shanghai Cancer Center, Shanghai, China. January 20, 2025.

102. “Selecting treatment options in early-stage NSCLC.” Invited International Speaker, Hong Kong International Oncology Forum (HKIOF) 2025 / 9th Annual Meeting of the International Society of Precision Cancer Medicine / International Society of Liquid Biopsy Symposium 2025, Hong Kong, China. June 21, 2025.

103. “Moving the needle forward in early-stage cancer clinical trials.” Grand Rounds Speaker, Department of Surgery, University of California Los Angeles (UCLA), Los Angeles, CA, USA. August 13, 2025.

104. “Precision Frontiers: Targeted Therapies in Early-Stage Lung Cancer – ALK Rearranged Non-Small Cell Lung Cancer.” Invited Speaker, 2025 World Conference on Lung Cancer (WCLC), International Association for the Study of Lung Cancer (IASLC), Barcelona, Spain. September 8, 2025.

105. “Surgeon perspectives in early-stage NSCLC.” Invited Speaker, New Horizons in Thoracic Malignancies: Merck Lung Symposium, European Society for Medical Oncology (ESMO) 2025, Berlin, Germany. October 18, 2025.

106. “Big tumors, bigger decisions: upfront surgery vs. neoadjuvant strategy in T4 NSCLC.” Invited Speaker, International Association for the Study of Lung Cancer (IASLC) / American Society of Clinical Oncology (ASCO) 2025 North America Conference on Lung Cancer, Chicago, IL, USA. December 5, 2025.

RESEARCH PAPERS – PEER-REVIEWED

1. Baumgartner F, Brundage B, Bleiweis M, Lee JM, Ferrario T, Georgiou D, Milliken J. Feasibility of ultrafast computed tomography in the early evaluation of coronary bypass patency. American Journal of Cardiac Imaging. 1996 Jul;10(3):170-174. PMID: 8914703.

2. Baumgartner F, Omari B, Lee JM, Bleiweis M, Snyder R, Robertson J, Sheppard B, Milliken J. Survival after trauma pneumonectomy: the pathophysiologic balance of shock resuscitation with right heart failure. The American Surgeon.1996 Nov;62(11):967-972. PMID: 8895724.

3. Lee JM, Baumgartner FJ, Shellans S, Butler J, French S. Degeneration and sarcomatous transformation of a retroperitoneal leiomyoma. European Journal of Surgery. 1996 Apr;162:337-340. PMID: 8739423.

4. Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor-α together with naïve dendritic cells elicits significant suppression of tumor growth without toxicity. Human Gene Therapy. 2001 Nov 20;12(17):2035-2049. doi:10.1089/10430340152677395. PMID: 11747595.

5. Korst RJ, Ailawadi M, Lee JM, Lee S, Yamada R, Mahtabifard A, Crystal RG. Adenovirus gene transfer vectors inhibit the growth of lymphatic tumor metastases independent of a therapeutic transgene. Human Gene Therapy. 2001 Sep 1;12(13):1639-1649. doi:10.1089/10430340152528138. PMID: 11535167.

6. Ailawadi M, Lee JM, Lee S, Hackett N, Crystal RG, Korst RJ. Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing. Surgery. 2002 Feb;131(2):219-227. doi:10.1067/msy.2002.118709. PMID: 11854705.

7. Lee JM, Mahtabifard A, Yamada R, Crystal RG, Korst RJ. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Clinical Cancer Research. 2002 Nov;8(11):3561-3569. PMID: 12429647.

8. Lee JM, Merritt RE, Mahtabifard A, Yamada R, Kikuchi T, Crystal RG, Korst RJ. Intratumoral expression of macrophage-derived chemokine induces CD4⁺ T cell-independent antitumor immunity in mice. Journal of Immunotherapy. 2003 Mar-Apr;26(2):117-129. doi:10.1097/00002371-200303000-00004. PMID: 12616103.

9. Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy, and chemoprevention of NSCLC. Future Oncology. 2007 Apr;3(2):149-153. doi:10.2217/14796694.3.2.149. PMID: 17381414.

10. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Review of Anticancer Therapy. 2007 Oct;7(10):1405-1421. doi:10.1586/14737140.7.10.1405. PMID: 17944566.

11. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM. Pre-clinical characterization of GMP-grade CCL21-gene-modified dendritic cells for application in a phase I trial in non-small cell lung cancer. Journal of Translational Medicine. 2008 Jul 22;6:38. doi:10.1186/1479-5876-6-38. PMID: 18644162; PMCID: PMC2507704.

12. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, John MS, Sharma S, Dubinett SM. Inflammation, epithelial-to-mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. Journal of Thoracic Oncology. 2008 Feb;3(2):107-110. doi:10.1097/JTO.0b013e3181630ece. PMID: 18303428.

13. Lee JM, Pou K, Sadow PM, Chen H, Hu B, Hewison M, Adams JS, Sugarbaker DJ, Fisher NDL. Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma. Endocrine Practice. 2008 Nov;14(8):1011-1016. doi:10.4158/EP.14.8.1011. PMID: 19095601.

14. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Critical Reviews in Oncology/Hematology. 2008 Jun;66(3):208-217. doi:10.1016/j.critrevonc.2008.01.004. PMID: 18304833; PMCID: PMC2483429.

15. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM. Smoking and lung cancer: the role of inflammation. Proceedings of the American Thoracic Society. 2008 Dec;5(8):811-815. doi:10.1513/pats.200809-100TH. PMID: 19017734; PMCID: PMC4080902.

16. Dubinett SM, Hazra S, Krysan K, Al-Shyoukh I, Feng J, Walser T, Heinrich E, Dohadwala M, Minna JD, Shay JW, Cui X, Yanagawa J, Lee JM, Horvath S, Gardner B, Ho CM, Sharma S, Sun R. New avenues for chemoprevention: a new paradigm to identify and personalize targeted combination chemoprevention for lung cancer. Journal of Thoracic Oncology. 2009;4(Suppl):S137-S139.

17. Lee JM, Garon E, Wong DT. Salivary diagnostics. Orthodontics and Craniofacial Research. 2009 Aug;12(3):206-211. doi:10.1111/j.1601-6343.2009.01454.x. PMID: 19627522; PMCID: PMC2909324.

18. Lee JM, Yanagawa J, Hazra S, Sharma S, Walser T, Garon E, Dubinett SM. Immunologic mechanisms in lung carcinogenesis and metastasis. In: Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. 2009:111-134.

19. Yanagawa J, Abtin F, Lai CK, Yeh M, Britten CD, Martinez D, Crisera CA, Holmes EC, Lee JM. Resection of thyroid cancer metastases to the sternum. Journal of Thoracic Oncology. 2009 Aug;4(8):1022-1025. doi:10.1097/JTO.0b013e3181adef20. PMID: 19633476.

20. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, Chia D, Goodglick L, Elashoff DA, Luo J, Magyar CE, Dohadwala M, Lee JM, St John MA, Strieter RM, Sharma S, Dubinett SM. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clinical Cancer Research. 2009 Nov 15;15(22):6820-6829. doi:10.1158/1078-0432.CCR-09-1558. PMID: 19887480; PMCID: PMC2783274.

21. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM. PGE₂ contributes to TGF-β–induced regulatory T-cell function in human non-small cell lung cancer. American Journal of Translational Research. 2010 Jun 30;2(4):356-367. PMID: 20733946; PMCID: PMC2923860. Co-first authors.

22. Dubinett SM, Lee JM, Sharma S, Mule JJ. Can effector cells be redirected to the site of the tumor? Cancer Journal.2010 Jul-Aug;16(4):325-335. doi:10.1097/PPO.0b013e3181eb33bc. PMID: 20693843; PMCID: PMC3076643.

23. Lee G, Lee JM, Gardner BK, Walser TC, Krysan K, Pak PS, Mao J, Hazra S, Dubinett SM. Blood-based biomarker profiles for detecting lung cancer. Journal of Thoracic Oncology. 2010;5(Suppl):S220-S221.

24. Pak PS, Yanagawa J, Abtin F, Wallace WD, Holmes EC, Lee JM. Surgical management of endobronchial solitary fibrous tumors. Annals of Thoracic Surgery. 2010 Aug;90(2):659-661. doi:10.1016/j.athoracsur.2010.02.024. PMID: 20667378; PMCID: PMC3158992.

25. Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, †Lee JM, †Dubinett SM. Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. American Journal of Translational Research. 2011 May 15;3(3):226-233. PMID: 21654877; PMCID: PMC3102566. †Co-senior authors.

26. Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. MUC1 peptide vaccine-mediated antitumor activity in non-small cell lung cancer. Expert Opinion on Biological Therapy. 2011 Aug;11(8):987-990. doi:10.1517/14712598.2011.598146. PMID: 21711210; PMCID: PMC3132083.

27. Kachroo P, Pak PS, Sandha HS, Lee C, Elashoff D, Nelson SD, Chmielowski B, Selch MT, Cameron RB, Holmes EC, Eilber FC, Lee JM. Single-institution multidisciplinary experience with surgical resection of primary chest wall sarcomas. Journal of Thoracic Oncology. 2012 Mar;7(3):552-558. doi:10.1097/JTO.0b013e31824176df. PMID: 22307013.

28. Kachroo P, Pak PS, Sandha HS, Nelson SD, Seeger LL, Cameron RB, Eilber FC, Lee JM. Chest wall sarcomas are accurately diagnosed by image-guided core needle biopsy. Journal of Thoracic Oncology. 2012 Jan;7(1):151-156. doi:10.1097/JTO.0b013e3182307f4c. PMID: 21900839.

29. Mehta NM, Selch M, Federman N, Chmielowski B, Lee JM, Eilber FC, Wang P, Wu J, Agazaryan N, Lee P. Safety and efficacy of stereotactic body radiation therapy for pulmonary metastases from high-grade sarcomas. Sarcoma.2013;2013:360214. doi:10.1155/2013/360214. PMID: 24198717; PMCID: PMC3807836.

30. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 2012 Mar;4(3):291-304. doi:10.2217/imt.11.178. PMID: 22401635; PMCID: PMC3324285.

31. Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets and Therapy. 2012 Oct 1;2012(1):7-12. doi:10.2147/ITT.S32617. PMID: 24791250; PMCID: PMC4004632.

32. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012 Jul 16;7(7):e40677. doi:10.1371/journal.pone.0040677. PMID: 22815789; PMCID: PMC3398024.

33. St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM. Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies. British Journal of Cancer. 2012 Aug 7;107(4):707-712. doi:10.1038/bjc.2012.203. PMID: 22828609; PMCID: PMC3419945.

34. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DTW. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Molecular and Cellular Proteomics.2012 Feb;11(2):M111.012112. doi:10.1074/mcp.M111.012112. PMID: 22096114; PMCID: PMC3277759.

35. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH, Wong DTW. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cellular and Molecular Life Sciences. 2012 Oct;69(19):3341-3350. doi:10.1007/s00018-012-1027-0. PMID: 22689099; PMCID: PMC4121486.

36. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, Dubinett SM, Lee JM. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research. 2013 Nov 25;32(1):97. doi:10.1186/1756-9966-32-97. PMID: 24274066; PMCID: PMC3906956.

37. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. American Journal of Translational Research. 2013 Aug 15;5(5):481-496. PMID: 23977408; PMCID: PMC3745436.

38. Mehta N, Selch M, Wang PC, Federman N, Lee JM, Eilber FC, Chmielowski B, Agazaryan N, Steinberg M, Lee P. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high-grade sarcoma. Sarcoma. 2013;2013:360214. doi:10.1155/2013/360214. PMID: 24198717; PMCID: PMC3807836.

39. Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opinion on Therapeutic Targets. 2013 May;17(5):481-483. doi:10.1517/14728222.2013.781585. PMID: 23506058; PMCID: PMC3758767.

40. Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S. CCL21 chemokine therapy for lung cancer. International Trends in Immunity. 2013 Jan;1(1):10-15. PMID: 25264541; PMCID: PMC4175527.

41. Rwigema JCM, Chen AM, Wang PC, Lee JM, Garon E, Lee P. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy. Clinical Lung Cancer. 2014 Jul;15(4):287-293. doi:10.1016/j.cllc.2014.01.004. PMID: 24594401.

42. Kishan AU, Cameron RB, Wang PC, Alexander S, Qi SX, Low DA, Kupelian PA, Steinberg ML, Lee JM, Selch MT, Lee P. Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma. Practical Radiation Oncology. 2015 Nov–Dec;5(6):366-373. doi:10.1016/j.prro.2015.07.010. PMID: 26432677.

43. Lin AY, Kotova S, Yanagawa J, Elbuluk O, Wang G, Kar N, Elashoff D, Grogan T, Cameron RB, Singh A, Chmielowski B, Federman N, Nelson SD, Lee P, Eilber FC, Lee JM. Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas. Journal of Thoracic and Cardiovascular Surgery. 2015 Jan;149(1):85-92. doi:10.1016/j.jtcvs.2014.09.039. PMID: 25312228.

44. Sharma S, Hu-Lieskovan S, Dubinett SM, Lee JM. Inflammation and lung cancer: addressing inflammation with immunotherapy. In: Inflammation and Lung Cancer. 2015:191-209.

45. Zhu LX, Davoodi M, Srivastava MK, Kachroo P, Lee JM, John MS, Harris-White M, Huang M, Strieter RM, Dubinett S, Sharma S. STIR agonist enhances vaccination responses in lung cancer. OncoImmunology. 2015 Apr 24;4(4):e992237. doi:10.4161/2162402X.2014.992237. PMID: 26137407; PMCID: PMC4485739.

46. Fishbein GA, Grimes BS, Xian RR, Lee JM, Barjaktarevic I, Xu H. Primary salivary duct carcinoma of the lung, mucin-rich variant. Human Pathology. 2016 Jan;47(1):150-156. doi:10.1016/j.humpath.2015.09.011. PMID: 26527521.

47. Onugha OI, Lee JM. Surgical treatment of lung cancer. Cancer Treatment and Research. 2016;170:77-104. doi:10.1007/978-3-319-40389-2_4. PMID: 27535390.

48. Toste PA, Lee JM. Limited resection versus lobectomy in early-stage non-small cell lung cancer. Journal of Thoracic Disease. 2016 Nov;8(11):E1511-E1513. doi:10.21037/jtd.2016.11.71. PMID: 28066646; PMCID: PMC5179473.

49. Ajijola OA, Hoover DB, Simerly TM, Brown TC, Yanagawa J, Biniwale RM, Lee JM, Sadeghi A, Khanlou N, Ardell JL, Shivkumar K. Inflammation, oxidative stress, and glial cell activation characterize stellate ganglia from humans with electrical storm. JCI Insight. 2017 Sep 21;2(18):e94715. doi:10.1172/jci.insight.94715. PMID: 28931760; PMCID: PMC5621921.

50. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8⁺ T-cell infiltration. Clinical Cancer Research. 2017 Aug 15;23(16):4556-4568. doi:10.1158/1078-0432.CCR-16-2821. PMID: 28468947; PMCID: PMC5599263.

51. Khakpour H, Shemin RJ, Lee JM, Buch E, Boyle NG, Shivkumar K, Bradfield JS. Atrioesophageal fistula after atrial fibrillation ablation: a single-center series. Journal of Atrial Fibrillation. 2017 Oct 31;10(3):1654. doi:10.4022/jafib.1654. PMID: 29250244; PMCID: PMC5725752.

52. Revels SL, Lee JM. Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) targeting the VEGF receptor (VEGFR): perspective on phase III clinical trials. Journal of Thoracic Disease. 2018 Feb;10(2):617-620. doi:10.21037/jtd.2018.01.105. PMID: 29607123; PMCID: PMC5864582.

53. Savitsky E, Oh SS, Lee JM. The evolving epidemiology and management of spontaneous pneumothorax. JAMA. 2018 Oct 9;320(14):1441-1443. doi:10.1001/jama.2018.12878. PMID: 30304415.

54. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary mucinous prostate adenocarcinoma lung metastasis detected by ⁶⁸Ga-PSMA-11 PET/CT. Clinical Genitourinary Cancer. 2019 Feb;17(1):e53-e55. doi:10.1016/j.clgc.2018.09.003. PMID: 30293922.

55. Sandler KA, Abtin F, Suh R, Cook RR, Felix C, Lee JM, Garon EB, Wu J, Luterstein EM, Agazaryan N, Tenn SE, Lee C, Steinberg ML, Lee P. A prospective phase II study evaluating safety and efficacy of combining stereotactic body radiation therapy with heat-based ablation for centrally located lung tumors. International Journal of Radiation Oncology, Biology, Physics. 2018 Jul 1;101(3):564-573. doi:10.1016/j.ijrobp.2018.03.011. PMID: 29893274.

56. Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J. Prostate cancer pulmonary metastasis presenting as a ground-glass pulmonary nodule on ⁶⁸Ga-PSMA-11 PET/CT. Clinical Nuclear Medicine. 2019 May;44(5):e353-e356. doi:10.1097/RLU.0000000000002499. PMID: 30789399.

57. Shirali AS, Grotts J, Elashoff D, Barjaktarevic I, Melamed KH, Van Hassel J, Cameron RB, Lee JM, Yanagawa J. Predictors of outcomes after thoracic surgery in orthotopic liver transplant recipients with pleural disease. Seminars in Thoracic and Cardiovascular Surgery. 2019 Autumn;31(3):604-611. doi:10.1053/j.semtcvs.2019.02.003. PMID: 30731193.

58. Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, Walser TC, Salehi-Rad R, Yanagawa J, Lee JM, Sharma S, Aberle D, Spira AE, Elashoff DA, Wallace WD, Fishbein MC, Dubinett SM. The immune contexture and genomic landscape of lung adenomatous premalignancy. Cancer Research. 2019 Oct 1;79(19):5022-5033. doi:10.1158/0008-5472.CAN-19-0153. PMID: 31142513; PMCID: PMC6774823.

59. Tsao AS, Jolly S, Lee JM. Updates in locally regionally advanced non-small cell lung cancer. ASCO Educational Book. 2019 Jan;39:553-562. doi:10.1200/EDBK_237839. PMID: 31099691.

60. Lee JM, Martin LW, Yang SC. Discussions in cardiothoracic treatment and care: what the surgeon needs to know about checkpoint inhibition in immunotherapy. Seminars in Thoracic and Cardiovascular Surgery. 2020 Summer;32(2):327-336. doi:10.1053/j.semtcvs.2019.12.009. PMID: 31899218.

61. Dusi V, Sorg JM, Gornbein J, Gima J, Yanagawa J, Lee JM, Vecerek N, Vaseghi M, Bradfield JS, De Ferrari GM, Shivkumar K, Ajijola OA. Prognostic impact of atrial rhythm and dimension in patients with structural heart disease undergoing cardiac sympathetic denervation for ventricular arrhythmias. Heart Rhythm. 2020 May;17(5 Pt A):714-720. doi:10.1016/j.hrthm.2019.12.007. PMID: 31837474; PMCID: PMC7196021.

62. Lee MH, Yanagawa J, Tran L, Walser TC, Bisht B, Fung E, Park SJ, Zeng G, Krysan K, Wallace WD, Paul MK, Girard L, Gao B, Minna JD, Dubinett SM, Lee JM. FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. American Journal of Translational Research. 2020 Feb 15;12(2):409-427. PMID: 32194893; PMCID: PMC7061839.

63. Kadam P, Singh RP, Davoodi M, Lee JM, St John M, Sharma S. Immune checkpoint blockade enhances the immune activity of therapeutic lung cancer vaccine. Vaccines (Basel). 2020 Nov 5;8(4):655. doi:10.3390/vaccines8040655. PMID: 33167311; PMCID: PMC7712481.

64. Dunphy KM, Ulloa JG, Benharash P, Lee JM, Baril DT. Aortoesophageal fistula treated with staged aortic stent graft and subsequent homograft interposition. Journal of Vascular Surgery Cases, Innovations and Techniques. 2020 Jun 30;6(3):313-316. doi:10.1016/j.jvscit.2019.11.008. PMID: 32637758; PMCID: PMC7330157.

65. Elliott IA, DeJesus M, Dobaria V, Vaseghi M, Ajijola OA, Shivkumar K, Hoftman NN, Benharash P, Lee JM, Yanagawa J. Minimally invasive bilateral stellate ganglionectomy for refractory ventricular tachycardia. JACC: Clinical Electrophysiology. 2021 Apr;7(4):533-535. doi:10.1016/j.jacep.2020.12.001. PMID: 33419708.

66. Sharma S, Kadam P, Singh RP, Davoodi M, St John M, Lee JM. CCL-21 DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer. AIMS Medical Science. 2021;8(4):269-275. doi:10.3934/medsci.2021022.

67. Elliott IA, DeJesus M, Dobaria V, Vaseghi M, Ajijola OA, Shivkumar K, Hoftman NN, Benharash P, Lee JM, Yanagawa J. Minimally invasive bilateral stellate ganglionectomy for refractory ventricular tachycardia. Annals of Thoracic Surgery. 2021 Apr;111(4):e295-e296. doi:10.1016/j.athoracsur.2020.09.030. PMID: 33419566.

68. Hayase J, Dusi V, Do D, Ajijola OA, Vaseghi M, Lee JM, Yanagawa J, Hoftman N, Revels S, Buch EF, Khakpour H, Fujimura O, Krokhaleva Y, Macias C, Sorg J, Gima J, Pavez G, Boyle NG, Shivkumar K, Bradfield JS. Recurrent ventricular tachycardia after cardiac sympathetic denervation: prolonged cycle length with improved hemodynamic tolerance and ablation outcomes. Journal of Cardiovascular Electrophysiology. 2020 Sep;31(9):2382-2392. doi:10.1111/jce.14624. PMID: 32558054; PMCID: PMC7719072.

69. Dusi V, Gornbein J, Do DH, Sorg JM, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JS, Buch E, Fujimura OA, Boyle NG, Yanagawa J, Lee JM, Shivkumar K, Vaseghi M. Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation. Journal of the American Heart Association. 2021 Jan 19;10(2):e018371. doi:10.1161/JAHA.120.018371. PMID: 33441022; PMCID: PMC7955320.

70. Lee JM, Kim AW, Marjanski T, Falcoz PE, Tsubi M, Wu YL, Sun SW, Gitlitz BJ. Important surgical and clinical endpoints in neoadjuvant immunotherapy trials in resectable non-small cell lung cancer. JTO Clinical and Research Reports. 2021 Aug 26;2(10):100221. doi:10.1016/j.jtocrr.2021.100221. PMID: 34746882; PMCID: PMC8552106.

71. Garrido P, Pujol JL, Kim ES, Lee JM, Tsuboi M, Gómez-Rueda A, Benito A, Moreno N, Gorospe L, Dong T, Blin C, Rodrik-Outmezguine V, Passos VQ, Mok TS. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncology. 2021 Apr;17(12):1459-1472. doi:10.2217/fon-2020-1098. PMID: 33648347.

72. Chi A, He X, Hou L, Nguyen NP, Zhu G, Cameron RB, Lee JM. Classification of non-small cell lung cancer’s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade. Cancers (Basel).2021 Jun 11;13(12):2924. doi:10.3390/cancers13122924. PMID: 34208113; PMCID: PMC8230820.

73. Zhou N, Deng J, Faltermeier C, Peng T, Mandl H, Revels S, Toste P, Cameron RB, Lee JM, Yanagawa J. The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening. Journal of Thoracic and Cardiovascular Surgery Open. 2022 Dec 13;13:379-388. doi:10.1016/j.xjon.2022.11.021. PMID: 37063117; PMCID: PMC10091284.

74. Lee JM, Tsuboi M, Brunelli A. Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer. Annals of Thoracic Surgery. 2022 Oct;114(4):1505-1515. doi:10.1016/j.athoracsur.2021.06.069. PMID: 34339672.

75. Shahrouki P*, Lee JM, Barclay J, Khan SN, Genshaft S, Abtin F, Dubinett SM, Lisberg A, Sharma S, Garon EB, Suh R. Technical feasibility and safety of repeated CT-guided trans-thoracic intratumoral injection of gene-modified cellular immunotherapy in metastatic non-small cell lung cancer. JTO Clinical and Research Reports. 2021 Oct 14;2(11):100242. doi:10.1016/j.jtocrr.2021.100242. PMID: 34806054; PMCID: PMC8581369. Equally contributed.

76. Faltermeier CM, Lee JM. Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint. Translational Lung Cancer Research. 2021 Dec;10(12):4328-4335. doi:10.21037/tlcr-21-830. PMID: 35070744; PMCID: PMC8743523.

77. Lee JM, Tsuboi M, Kim ES, Mok T SK, Garrido P. Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1β and PD-1 inhibition. Future Oncology. 2022 Sep;18(27):3085-3100. doi:10.2217/fon-2021-1567. PMID: 36004638.

78. Liang W et al. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Translational Lung Cancer Research. 2022 Sep;11(9):1742-1762. doi:10.21037/tlcr-22-617. PMID: 36248334; PMCID: PMC9554679.

79. Chaft JE et al.; Lee JM (Thoracic Surgery Co-Chair, LCMC3 Trial). Neoadjuvant treatment of non-small cell lung cancer with atezolizumab. Nature Medicine. 2022 Oct;28(10):2155-2161. doi:10.1038/s41591-022-01962-5.

80. Lee JM. Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: the unmet need. Journal of Thoracic and Cardiovascular Surgery. 2023 Jan;165(1):335-336. doi:10.1016/j.jtcvs.2022.07.019. PMID: 35987868.

81. Rusch VW et al.; Lee JM (Thoracic Surgery Co-Chair, LCMC3 Trial). Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter study of atezolizumab as neoadjuvant therapy in resectable NSCLC. Journal of Thoracic and Cardiovascular Surgery. 2022 Oct 8:S0022-5223(22)01055-8. doi:10.1016/j.jtcvs.2022.10.007. PMID: 36369159.

82. Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early NSCLC in the USA. Future Oncology. 2023 Jan;19(1):37-47. doi:10.2217/fon-2022-0845. PMID: 36662515.

83. Sridharan A, Tang A, Sorg JM, Hoftman NN, Lee JM, Yanagawa J, Vaseghi M. Effect of bilateral cardiac sympathetic denervation on burden of premature ventricular contractions. Circulation: Arrhythmia and Electrophysiology. 2023 Apr;16(4):e011546. doi:10.1161/CIRCEP.122.011546. PMID: 36916281; PMCID: PMC10132769.

84. Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS. Economic burden of recurrence among resected Medicare patients with early-stage NSCLC. JTO Clinical and Research Reports. 2023 Feb 25;4(4):100487. doi:10.1016/j.jtocrr.2023.100487. PMID: 37007869; PMCID: PMC10050774.

85. Lee JM, Vallières E, Ding B et al. Safety and tolerability of adjuvant atezolizumab following chemotherapy in patients with stage II–IIIA NSCLC after pneumonectomy or bilobectomy: Results from IMpower010. Journal of Thoracic and Cardiovascular Surgery. 2023 Jan 21;S0022-5223(23)00080-6. doi:10.1016/j.jtcvs.2023.01.012.

86. Wu TC et al.; Lee JM (co-author). Safety and efficacy results from iSABR, a phase I study of stereotactic ablative radiotherapy with durvalumab for medically inoperable early-stage NSCLC. International Journal of Radiation Oncology Biology Physics. 2023 Apr 5:S0360-3016(23)00325-5. doi:10.1016/j.ijrobp.2023.03.069. PMID: 37023987.

87. Expert Consensus Panel; Kidane B et al.; Lee JM. AATS 2023 Expert Consensus Document: Staging and multidisciplinary management of early-stage NSCLC. Journal of Thoracic and Cardiovascular Surgery. 2023 Sep;166(3):637-654. doi:10.1016/j.jtcvs.2023.04.039. PMID: 37306641.

88. Moghanaki D, Lisberg A, Oh S, Lee JM. Unresectable stage III NSCLC should not be treated with neoadjuvant therapy and re-evaluated for resection. Journal of Thoracic Oncology. 2023 Sep;19(9):1129-1133. doi:10.1016/j.jtho.2023.06.005. PMID: 37599046.

89. Lee JM, Vallières E, Ding B et al. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II–IIIA NSCLC in the IMpower010 trial. Journal of Thoracic and Cardiovascular Surgery. 2023 Sep;166(3):655-666.e7. doi:10.1016/j.jtcvs.2023.01.012. PMID: 36841745.

90. Lee JM, McNamee CJ, Toloza E et al. Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives. Journal of Thoracic Oncology. 2023 Nov;18(11):1458-1477. doi:10.1016/j.jtho.2023.07.006. PMID: 37451404; PMCID: PMC11040203.

91. Dacic S et al.; Lee JM. AI-powered assessment of pathologic response to neoadjuvant atezolizumab in NSCLC: Results from LCMC3. Journal of Thoracic Oncology. 2023 Dec 7:S1556-0864(23)02415-2. doi:10.1016/j.jtho.2023.12.010. PMID: 38070597.

92. Wu TC et al.; Lee JM. Accelerated hypofractionated chemoradiation followed by SABR boost for locally advanced, unresectable NSCLC: A nonrandomized controlled trial. JAMA Oncology. 2024 Jan 11:e236033. doi:10.1001/jamaoncol.2023.6033. PMID: 38206614; PMCID: PMC10784998.

93. Chaft JE et al.; Lee JM. Author Correction: Neoadjuvant atezolizumab for resectable NSCLC — open-label phase II trial. Nature Medicine. 2024 Jan;30(1):303. doi:10.1038/s41591-023-02627-7. Erratum for Nat Med 2022;28(10):2155-2161. PMID: 37816821; PMCID: PMC10803254.

94. Lee JM. Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable NSCLC: How do I choose? Importance of immune biomarkers and molecular testing. Journal of Thoracic and Cardiovascular Surgery. 2024 Apr 20:S0022-5223(24)00362-3. doi:10.1016/j.jtcvs.2024.03.034. PMID: 38649111.

95. Lee JM, To TM, Wang S, Lin CW, Johnson A, Meyer CS, Lee JS. Clinical and economic outcomes associated with lymph node examination status in early-stage NSCLC: A real-world US study. Translational Lung Cancer Research. 2024 Apr 30;13(4):1821-1833. doi:10.21037/tcr-23-1388. PMID: 38737679.

96. Nikitas J et al.; Lee JM. Pathophysiology and management of chest wall pain after local therapies for lung cancer. JTO Clinical and Research Reports. 2024 May 16;5(7):100690. doi:10.1016/j.jtocrr.2024.100690. PMID: 39077624; PMCID: PMC11284817.

97. Girard N et al.; Lee JM. Comparative efficacy of neoadjuvant nivolumab plus chemotherapy versus conventional treatments in resectable NSCLC: systematic review and network meta-analysis. Cancers (Basel). 2024 Jul 8;16(13):2492. doi:10.3390/cancers16132492. PMID: 39001554.

98. Lee JM. Sublobar resection vs lobectomy for high-risk stage I NSCLC. JAMA Oncology. 2024 Aug 1. doi:10.1001/jamaoncol.2024.2294. PMID: 39088204.

99. Solomon BJ et al.; Lee JM. Impact of the tumor microenvironment on IL-1β blockade in NSCLC: Biomarker analyses from CANOPY-1 and CANOPY-N trials. Cancer Research Communications. 2025 Mar 21. doi:10.1158/2767-9764.CRC-24-0490. PMID: 40116353.

100. Lee JM, Pujol J, Zhang J et al. CANOPY-N: Phase II study of canakinumab or pembrolizumab, alone or in combination, as neoadjuvant therapy in resectable stage IB–IIIA NSCLC. JTO Clinical and Research Reports. 2025 Jun 13;6(8):100859. doi:10.1016/j.jtocrr.2025.100859. PMID: 40810132.

101. Lee JM, Brunelli A, Cummings AL, Felip E, Shu CA, Solomon BJ, Tsuboi M, Wakelee H, Saqui A, Wu YL, Li PC, Gitlitz BJ. Phase III trials of neoadjuvant, perioperative, and adjuvant chemoimmunotherapy for resectable early-stage NSCLC: Comprehensive review and detailed

RESEARCH PAPERS – PEER-REVIEWED (SUBMITTED)

1. Owen DH, Chaft JE, Grindheim JM, Nicholas A, Haura EB, Toloza EM, Waqar SN, Patterson GA, Finley D, Blasberg J, Raz D, Salgia R, Lee JM, Bunn PA, Wistuba II, Kwiatkowski DJ, Hirsch FR, Gopalakrishnan A, Brandao E, Shum E, Nagasaka M, Gainor JF, McNamee CJ, Johnson BE, Johnson A, Schulze K, Kris MG, Rusch VW, Carbone DP.
Neoadjuvant atezolizumab for resectable NSCLC: Final disease-free and overall survival results and circulating tumor DNA analysis from the open-label Phase II LCMC3 study.
Submitted, 2025 (Lancet Oncology).

2. Spicer JD, Peters S, Gainor JF, Chaft JE, Bestvina CM, Lee JM, Marron TU, Khattak MA, Ojalvo LS, Banerjee JK, Wang Z, Deng X, Shariati N, Keller SM, Cascone T.
Study designs for INTerpath-002 and INTerpath-009 of adjuvant Intismeran Autogene plus Pembrolizumab for NSCLC.
Submitted, 2025 (Annals of Thoracic Surgery: Short Reports).

BOOK CHAPTERS

1. Lee JM, Dubinett SM, Sharma S. Immunologic Approaches to Lung Cancer Therapy. In: Roth JA, Cox JD, Hong WK (eds.). Lung Cancer, 3rd Edition. Blackwell Publishing; 2008:334–351.

2. Lee JM, Sugarbaker DJ. Extrapleural Pneumonectomy for Diffuse Malignant Pleural Mesothelioma and Other Diffuse Pleural Malignancies. In: Sugarbaker DJ, Bueno R, Krasna M, Mentzer S, Zellos L (eds.). Adult Chest Surgery. McGraw-Hill; 2009.

3. Lee JM, Yanagawa Y, Hazra S, Walser T, Garon E, Dubinett SM. Immunologic Mechanisms in Lung Carcinogenesis and Metastasis. In: Keshamouni V, Arenberg D, Kalemkerian G (eds.). Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. Springer; 2009:111–134.

4. Walser TC, Yanagawa J, Garon E, Lee JM, Dubinett SM. Lung Cancer: Prevention, Management, and Emerging Therapies. In: Stewart DJ (ed.). Tumor Microenvironment. Humana Press; 2009:27–70.

5. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Myeloid cell-mediated programming of the tumor microenvironment. In: Biswas S (ed.). Tumor Microenvironment and Myelomonocytic Cells.InTechOpen; 2012:137–156. ISBN: 978-953-51-0439-1.

6. Sharma S, Srivastava M, Harris-White M, Schaue D, St John M, Zhang G, Lee P, Lee JM, Dubinett S. CCL21. In: Marshall JL (ed.). Cancer Therapeutic Targets. Springer; 2012.

7. Lee JM, Dubinett SM, Sharma S. Immunologic Approaches to Lung Cancer Therapy. In: Roth JA, Cox JD, Hong WK (eds.). Lung Cancer, 4th Edition. Blackwell Publishing; 2014.

8. Lee JM, Sugarbaker DJ. Extrapleural Pneumonectomy. In: Sugarbaker DJ, Bueno R, Colson JC, Jaklitsch MT, Krasna M, Mentzer SJ (eds.). Adult Chest Surgery, 2nd Edition. McGraw-Hill; 2015.

9. Velotta J, Lee JM. Sternal and Clavicular Chest Wall Resection and Reconstruction. In: Sugarbaker DJ, Bueno R, Colson JC, Jaklitsch MT, Krasna M, Mentzer SJ (eds.). Adult Chest Surgery, 2nd Edition. McGraw-Hill; 2015.

10. Sharma S, Hu-Lieskovan S, Dubinett SM, Lee JM. Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. In: Dubinett SM (ed.). Inflammation and Lung Cancer, 1st Edition. Springer; 2015.

11. Lee JM, Sugarbaker DJ. Extrapleural Pneumonectomy. In: Sugarbaker DJ, Bueno R, Burt BM, Groth SS, Loor G, Wolf AS (eds.). Adult Chest Surgery, 3rd Edition. McGraw-Hill; 2020.

12. Lee JM. Sternal and Clavicular Chest Wall Resection and Reconstruction. In: Sugarbaker DJ, Bueno R, Burt BM, Groth SS, Loor G, Wolf AS (eds.). Adult Chest Surgery, 3rd Edition. McGraw-Hill; 2020.

ABSTRACTS

1. Baumgartner J, Lee JM, Bleiweis M, Ferrario T, Georgiou D, Milliken J, Brundage B.
Ultrafast CT in the early evaluation of suspected MI after coronary bypass.
Annual Meeting of the American College of Surgeons, Southern California Chapter. January 1995.

2. Laks H, Blitz A, Drinkwater DC, Kobashigawa J, Fonarow G, Hamilton L, Duong TH, Maddahi J, Chung JY, Lee JM, Walden J.
Coronary revascularization versus heart transplantation for ischemic cardiomyopathy.
Third International Congress on Heart Failure Mechanisms and Management. Journal of Heart Failure. May 1995;2(1).

3. Omari B, Baumgartner F, Lee JM, Bleiweis M, Sheppard B, Robertson J, Milliken J.
Trauma pneumonectomy revisited: The pathophysiologic balance of shock resuscitation with right heart failure.
Annual Meeting of the American College of Surgeons, Southern California Chapter. January 1996.

4. Blitz A, Laks H, Drinkwater DC, Fonarow G, Hamilton M, Duong TH, Maddahi J, Chung JY, Lee JM, Walden J, Kobashigawa J.
Revascularization versus transplantation for ischemic cardiomyopathy.
Thirty-Second Annual Meeting of the Society of Thoracic Surgeons. January 1996.

5. Ivandic B, deBeer FC, deBeer M, Leitinger N, Wang XP, Castellani L, Lee JM, Hama S, Navab M, Fogelman AM, Lusis AJ.
Transgenic mice overexpressing secretory phospholipase A2 develop markedly increased aortic fatty streak lesions.
Sixty-Ninth Annual Scientific Sessions of the American Heart Association. Circulation. 1996;94(8):I-152. November 1996.

6. Ailawadi M, Lee JM, Lee S, Crystal RG, Korst RJ.
Adenovirus vector administration inhibits the progression of lymphatic metastasis of murine metastatic tumors.
American Society of Gene Therapy, Third Annual Meeting. Molecular Therapy. 2000;1(5):S264–S265. May 2000.

7. Lee JM, Ramalingam R, Kikuchi T, Ailawadi M, Lee S, Crystal RG, Korst RJ.
NF-κB gene transfer to dendritic cells enhances their activation and in vivo antitumor effect when combined with suicide gene therapy.
Eighth Annual Meeting of the European Society of Gene Therapy. Journal of Gene Medicine. 2000;2(5):103. October 2000.

8. Korst RJ, Ailawadi M, Lee JM, Lee S, Hackett NR, Crystal RG.
Adenovirus vector-mediated transfer of the VEGF cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice.
Surgery. 2002 Feb;131(2):219–227. doi:10.1067/msy.2002.118709. PMID: 11854705.

9. Lee JM, Kikuchi T, Mahtabifard A, Yamada R, Crystal RG, Korst RJ.
In vivo transfer of the macrophage-derived chemokine (MDC) gene to established murine tumors inhibits tumor growth and induces a cytotoxic T-lymphocyte response.
Ninety-Seventh International Conference of the American Thoracic Society. American Journal of Respiratory and Critical Care Medicine. 2001;163(5):A529. April 2001.

10. Lee JM, Mahtabifard A, Kianmanesh R, Kikuchi T, Yamada R, Crystal RG, Korst RJ.
Intratumoral administration of dendritic cells genetically modified to express truncated p65 NF-κB induces regression of established tumors.
American Society of Gene Therapy, Fourth Annual Meeting. Molecular Therapy. 2001;3(5):S146. May 2001. Oral Presentation.

11. Lee JM, Mahtabifard A, Kikuchi T, Yamada R, Crystal RG, Korst RJ.
Adenovirus-mediated gene transfer of macrophage-derived chemokine to pre-existing murine tumors inhibits tumor growth independent of CD4⁺ T lymphocytes.
American Society of Gene Therapy, Fourth Annual Meeting. Molecular Therapy. 2001;3(5):S22–S23. May 2001. Oral Presentation.

12. Lee JM, Baratelli F, Kurimoto P, Sharma S, Dubinett SM.
Dendritic cell-based genetic immunotherapy for lung cancer.
British Association for Lung Research – Gene & Stem Cell Therapies for Lung Diseases Meeting. Maynooth (Ireland), September 2007.

13. Yanagawa J, Walser TC, Lee JM, Dohadwala M, Zhu L, Krysan K, Luo J, Sharma S, Dubinett SM.
Transcriptional repressor Snail promotes tumor growth and angiogenesis in human non-small cell lung cancer.
94th Annual Clinical Congress, American College of Surgeons. Journal of the American College of Surgeons.2008;207(3):S47. October 2008.

14. Yanagawa J, Walser TC, Lee JM, Luo J, Liu M, Fishbein MC, Goodglick L, Zhu L, Sharma S, Minna JD, Shay JW, Strieter RM, Dubinett SM.
The zinc-finger E-box-binding transcriptional repressor Snail links inflammation, angiogenesis, and EMT in human non-small cell lung cancer.
National Cancer Institute (NCI) Translational Science Meeting. November 2008.

15. Dubinett SM, Hazra S, Krysan K, Al-Shyoukh I, Feng J, Walser TC, Heinrich E, Dohadwala M, Minna JD, Shay JW, Cui X, Yanagawa J, Lee JM, Horvath S, Gardner B, Ho CM, Sharma S, Sun R.
New avenues for chemoprevention: A new paradigm to identify and personalize targeted combination chemoprevention for lung cancer.
13th World Conference on Lung Cancer (WCLC). August 2009.

16. Lee G, Lee JM, Gardner BK, Walser TC, Krysan K, Pak PS, Mao JT, Hazra S, Dubinett SM.
Blood-based biomarker profiles for detecting lung cancer.
AACR–IASLC Joint Conference on Molecular Origins of Lung Cancer, Coronado, CA. Abstract A13. January 2010.

17. St. John M, Wang G, Luo J, Dohadwala M, Munaim Q, Lee JM, Burrows F, Zaknoen S, Dubinett SM.
Apricoxib upregulates 15-PGDH and PGT in HNSCC.
AACR 101st Annual Meeting, Washington, DC. Proceedings of the American Association for Cancer Research. April 2010;4459.

18. Lee JM, Garon EB, Baratelli F, Schaue D, Pak PS, Wallace WD, Suh R, Abtin F, Zeng G, Dubinett SM.
Phase I trial of CCL21 gene-modified dendritic cells in non-small cell lung cancer.
ASCO Annual Meeting, Chicago, IL. Journal of Clinical Oncology. 2010;28(15s):TPS157. June 2010.

19. Xiao H, Zhang L, Zhou M, Lee JM, Akin D, Wong D.
Salivary proteomic biomarkers for lung cancer detection.
American Association of Dental Research Annual Meeting, Washington, DC. March 2010.

20. Zhang L, Kachroo P, Cui X, Hazra S, Walser TC, Minna JD, Sharma S, Dubinett SM, Lee JM.
Interleukin-27 inhibits epithelial-mesenchymal transition in lung carcinogenesis.
AACR 102nd Annual Meeting. April 2011.

21. Kachroo P, Zhang L, Walser TC, Cui X, Hazra S, Lin Y, Minna JD, Dubinett SM, Lee JM.
Interleukin-27 inhibits angiogenesis in lung carcinogenesis.
AACR 102nd Annual Meeting. April 2011.

22. Kachroo P, Lee M, Lee G, Krysan K, Sharma S, Dubinett SM, Lee JM.
IL-27-mediated inhibition of epithelial-to-mesenchymal transition is augmented by STAT1 activator 2-(1,8-naphthyridin-2-yl) phenol (2-NP) in human NSCLC.
7th Annual Academic Surgical Congress. February 2012.

23. Kachroo P, Lee M, Lee G, Krysan K, Walser TC, Sharma S, Zaknoen S, Dubinett SM, Lee JM.
Apricoxib, a selective COX-2 inhibitor, suppresses IL-27-mediated STAT3 activation and potentiates inhibition of epithelial-to-mesenchymal transition in human NSCLC.
AACR 103rd Annual Meeting. March 2012.

24. Lee M, Kachroo P, Lee G, Krysan K, Walser TC, Park S, Larsen JE, Minna JD, Dubinett SM, Lee JM.
K-RAS mutation (K-RASv12) inhibits IL-27-mediated mesenchymal-to-epithelial transition in bronchial epithelial cells.
AACR 103rd Annual Meeting. March 2012.

25. Rabbani S, Suh R, Lee JM, Gutierrez A, Brown K, Abtin F.
A multimodality imaging approach to differentiate thymic hyperplasia from thymic neoplasm.
Society of Thoracic Radiology Annual Meeting. March 2012.

26. Elbuluk O, Kachroo P, Lee JM.
Achieving long-term survival with resection of metastatic chest wall sarcomas.
22nd Annual Scientific Assembly of the Society of Black Academic Surgeons. April 2012.

27. Lee JM, Garon EB, Baratelli R, Lee M, Kachroo P, Purcell C, Pak PS, Rosen F, Mortazavi F, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM.
Preliminary results of a Phase I trial of trans-thoracic injection of CCL21 gene-modified dendritic cells in human NSCLC demonstrate induction of tumor-specific immune responses.
NCI Lung Cancer SPORE Workshop. July 2012.

28. Krysan K, Walser TC, Kusko R, Gardner BK, Spira AP, Lenburg ME, Brothers JF, O’Hearn J, Reckamp KL, Mao JT, Purcell C, Lee JM, Garon EB, Dubinett SM.
PGE₂-dependent upregulation of the miR-19–72 cluster contributes to apoptosis resistance in NSCLC.
NCI Lung Cancer SPORE Workshop. July 2012.

29. Mehta N, Selch M, Federman N, Chmielowski B, Lee JM, Eilber FC, Wang J, Wu J, Agazaryan N, Lee P.
Safety and efficacy of stereotactic body radiation therapy for pulmonary metastases from high-grade sarcomas.
54th Annual Meeting of ASTRO. October 2012.

30. Lee JM, Garon EB, Lee MH, Wang G, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM.
Results of a Phase I trial of trans-thoracic injection of CCL21 gene-modified dendritic cells in human NSCLC.
NCI Lung Cancer SPORE Workshop. July 2013.

31. Aberle D, Genshaft S, Abtin F, Wallace WD, Oh A, Singharuksa S, Elashoff D, Lee JM, Dubinett S.
An imaging-based semantic atlas for characterization of non-small cell lung cancer.
NCI Lung Cancer SPORE Workshop. July 2013.

32. Lee P, Felix C, Abtin F, Wu J, Suh R, Tenn S, Lee C, Wang P, Lee JM, Garon EB, Basehart V, Agazaryan N, Steinberg M.
Early outcomes from a Phase II trial evaluating SBRT combined with RFA for centrally located lung tumors.
International Journal of Radiation Oncology, Biology, Physics. September 2014;90(1 Suppl):S29.

33. Lee JM, Garon EB, Lee MH, Wang G, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM.
Phase I trial of trans-thoracic injection of CCL21 gene-modified dendritic cells in human NSCLC.
9th Annual Academic Surgical Congress (ASC). February 2014.

34. Lee JM, Lee MH, Yanagawa J, Kachroo P, Wang G, Park S, Lee G, Walser TC, Kostyantyn K, Sharma S, Dubinett SM.
IL-27 enhances SOCS3 expression and inhibits STAT3 activation, resulting in inhibition of cell migration in premalignant KRAS-mutated human bronchial epithelial cells.
American Association for Thoracic Surgery (AATS) 94th Annual Meeting. May 2014.

36. Lin A, Yanagawa J, Elbuluk O, Kotova S, Wang G, Kar N, Elashoff D, Grogan T, Lee P, Eilber FC, Lee JM.
Risk stratification of prognostic variables in patients undergoing lung metastasectomy for soft tissue and bone sarcomas.
Western Thoracic Surgical Association (WTSA) 40th Annual Meeting. June 2014.

37. Lee JM, Garon EB, Lee MH, Wang G, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM.
Immune response in Phase I trial of CCL21 gene-modified dendritic cells correlates with PD-L1.
National Cancer Institute (NCI) Lung Cancer SPORE Workshop. July 2014.

38. Lee JM, Garon EB, Lee MH, Wang G, Abtin F, Suh R, Wallace WD, Zeng G, Sharma S, Dubinett SM.
PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene-modified dendritic cell therapy in lung cancer.
29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2014. Journal for ImmunoTherapy of Cancer. 2014;2(Suppl 3):O20.

39. Lee MH, Yanagawa J, Wu S, Walser TC, Wang G, Goldman JW, Garon EB, Zeng G, Sharma S, Minna JD, Carbone DP, Dubinett SM, Lee JM.
ERK activation mediates increased PD-L1 expression in KRAS-mutated premalignant human bronchial epithelial cells.
16th World Conference on Lung Cancer (WCLC). September 2015.

40. Garon EB, McKenna R, Dering J, Wolf B, Pitts S, Kamranpour N, Chen H, Lisberg A, Cameron RB, Lee JM, Dubinett SM, Slamon DJ.
Characterization of PD-L1 expression related to unique genes in NSCLC tissue samples.
16th World Conference on Lung Cancer (WCLC). Journal of Thoracic Oncology. 2015;10(9 Suppl 2):MINI02.09.

41. Lee MH, Yanagawa J, Li R, Walser TC, Kostyantyn K, Wang G, Goldman JW, Garon EB, Zeng G, Sharma S, Minna JD, Carbone DP, Dubinett SM, Lee JM.
Increased PD-L1 expression in KRAS-mutated premalignant bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation.
Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting. November 2015. Journal for ImmunoTherapy of Cancer. 2015;3(Suppl 2):P305.

42. Kishan AU, Cameron R, Wang J, Alexander S, Qi X, Kupelian PA, Steinberg ML, Lee JM, Selch MT, Lee P.
Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.
ASTRO Annual Meeting. November 2015. International Journal of Radiation Oncology, Biology, Physics. 2015;93(3 Suppl):E397.

43. Salehi-Rad R, Walser TC, Yakobian N, Park SJ, Lee MH, Lee JM, Sharma S, Dubinett SM.
Intratumoral CCL21 and checkpoint blockade cooperatively inhibit NSCLC tumor growth in vivo to a greater extent than monotherapy.
Journal of Thoracic Oncology. February 2016;11(Suppl 2):S41.

44. Lee MH, Yanagawa J, Walser TC, Goldman JW, Garon EB, Zeng G, Sharma S, Gao B, Minna J, Dubinett SM, Lee JM.
FRA1 contributes to ERK-mediated increased PD-L1 expression in KRAS-mutated premalignant human bronchial epithelial cells.
AACR 107th Annual Meeting. April 16–20, 2016. Cancer Research. July 2016. DOI: 10.1158/1538-7445.AM2016-2324.

45. Lee JM, Lee MH, Garon EB, Goldman JW, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Wallace WD, Zeng G, Elashoff DA, Sharma S, Dubinett SM.
Phase I trial of in situ vaccination with CCL21 gene-modified dendritic cells induces peripheral tumor-specific immune responses and tumor-infiltrating CD8⁺ T cells in lung cancer.
Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting. November 2016.

46. Lee JM, Lee MH, Garon EB, Goldman JW, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Wallace WD, Zeng G, Elashoff DA, Sharma S, Dubinett SM.
PD-L1 expression correlates with tumor-infiltrating CD8⁺ T cells in a Phase I trial of in situ vaccination using CCL21 gene-modified dendritic cells.
17th World Conference on Lung Cancer (WCLC), IASLC. December 2016.

47. Lisberg A, McKenna R, Dering J, Chen H, Hou D, Kamranpour N, Velez M, Cameron R, Lee JM, Dubinett S, Slamon D.
Frequent high TIM-3 (HAVCR2) expression in resected NSCLC specimens, most notably in adenocarcinoma histology.
World Conference on Lung Cancer (WCLC) 2016. Journal of Thoracic Oncology. 2017;12(1 Suppl):S835.

48. Lisberg A, McKenna R, Dering J, Chen H, Kamranpour N, Hou D, Velez M, Cameron R, Lee JM, Dubinett S, Slamon D.
Coexpression of CD8α and PD-L1 frequently observed in resected NSCLC tumors from smokers.
World Conference on Lung Cancer (WCLC) 2016. Journal of Thoracic Oncology. 2017;12(1 Suppl):S614–S615.

49. Lee JM, Garon EB, Goldman JW, Abtin F, Suh R, Wallace WD, Zeng G, Elashoff DA, Sharma S, Dubinett SM.
Phase I trial of CCL21 gene-modified dendritic cells in lung cancer elicits immune responses.
Lung Cancer SPORE Workshop. 2017.

50. Owen DH, Bunn PA, Johnson BE, Kwiatkowski DJ, Kris MG, Wistuba II, Gandhi M, Phan S, Shames DS, Schulze K, Yu W, Aisner D, Chaft JE, Garon EB, Lee JM, Minna JD, Rusch VW, Reckamp KL, Wozniak AJ, Carbone DP, LCMC3 Investigators.
A Phase II study of atezolizumab as neoadjuvant and adjuvant therapy in resectable NSCLC.
ASCO Annual Meeting. Journal of Clinical Oncology. 2017;35(Suppl):TPS8580.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

51. Yanagawa J, Fung E, Lee M, Wallace WD, Fishbein MC, Paul M, Krysan K, Minna JD, Guo R, Elashoff D, Dubinett SM, Lee JM.
Premalignant lung lesions demonstrate enhanced PD-L1 upregulation in response to interferon-gamma exposure.
AACR–IASLC Joint Conference: Lung Cancer Translational Science from Bench to Clinic. January 8–11, 2018. Co-Senior Authors.

52. Rusch VW, Chaft JE, Johnson B, Wistuba II, Kris MG, Lee JM, Bunn PA, Kwiatkowski DJ, Reckamp KL, Finley DJ, Haura EB, Waqar SN, Doebele RC, Garon EB, Blasberg J, Nicholas A, Schulze K, Phan SC, Gandhi M, Carbone DP.
Neoadjuvant atezolizumab in resectable NSCLC: Initial results from a multicenter study (LCMC3).
ASCO Annual Meeting. Journal of Clinical Oncology. 2018;36(Suppl):8541.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

53. Rusch VW, Chaft JE, Johnson BE, Wistuba I, Kris MG, Lee JM, Bunn PA, Kwiatkowski DJ, Reckamp KL, Finley DJ, Haura EB, Waqar SN, Doebele RC, Garon EB, Blasberg J, Nicholas A, Schulze K, Phan SC, Johnson A, Carbone DP.
Neoadjuvant atezolizumab in resectable NSCLC: Updated results from a multicenter study (LCMC3).
19th World Conference on Lung Cancer (WCLC), IASLC. Toronto, Canada. September 23–26, 2018.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

54. Oezkan F, He K, Owen D, Pietrzak M, Kitzler R, Pearson R, Nicholas A, Bunn P, Kris M, Kwiatkowski DJ, Johnson BE, Hirsch FR, Wistuba I, Rusch V, Lee JM, Johnson A, Schulze K, Shames DS, Lozanski G, Carbone DP.
Comprehensive peripheral blood immunophenotyping during neoadjuvant immunotherapy with atezolizumab in NSCLC.
19th World Conference on Lung Cancer (WCLC), IASLC. Toronto, Canada. September 23–26, 2018.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

55. Oezkan F, He K, Owen D, Pietrzak M, Rusch VW, Chaft JE, Kitzler R, Schulze K, Johnson A, Nicholas A, Bunn PA Jr., Kris MG, Kwiatkowski DJ, Johnson BE, Wistuba II, Lee JM, Hirsch FR, Lozanski G, Carbone DP.
Neoadjuvant atezolizumab in resectable NSCLC: Updated clinical and immunophenotyping results from a multicenter trial.
ASCO–SITC Clinical Immuno-Oncology Symposium. February 28–March 2, 2019.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

56. Lee JM, Nicholas A, Isbell JM, Molena D, Patterson GA, Kozower B, Puri V, Toloza EM, Kim JY, Raz DJ, Merritt RE, Finley DJ, McNamee CJ, Baciewicz FA, Blasberg J, Mitchell JD, Weyant MJ, Scott C, Pass HI, Johnson A, Phan S, Schulze K, Bunn PA, Hirsch FR, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Carbone DP, Rusch VW.
Updated results of a multicenter Phase II trial of neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC.
American Association for Thoracic Surgery (AATS) Annual Meeting. 2019.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

57. Lee P, Luterstein E, Goldman J, Garon E, Lee JM, Felix C, Cao M, Tenn SE, Low D, Kupelian PA, Steinberg ML.
Accelerated hypofractionated chemoradiation followed by SABR boost (HyCRT-SABR) for locally advanced unresectable NSCLC: A prospective Phase II study.
ASTRO 61st Annual Meeting. Chicago, IL. 2019. DOI: 10.1016/j.ijrobp.2019.06.469.

58. Tran K, Dusi V, Sorg J, Hoftman N, Yanagawa J, Lee JM, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JB, Buch EB, Fujimura OA, Boyle NG, Shivkumar K, Vaseghi M.
Outcomes of cardiac sympathetic denervation for ventricular tachycardia: Impact of urgency and hemodynamic stability.
Heart Rhythm Society Scientific Sessions. 2019.

59. Dusi V, Gornbein J, Sorg J, Khakpour H, Krokhaleva Y, Ajijola OA, Macias C, Bradfield JS, Buch EF, Fujimura OA, Boyle NG, Yanagawa J, Lee JM, Shivkumar K, Vaseghi M.
Quantifying the benefit of cardiac sympathetic denervation in patients with monomorphic ventricular tachycardia referred for catheter ablation: An effect size analysis.
American Heart Association Scientific Sessions. November 11, 2019. Circulation. 2019;140:A13872.

60. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Li R, Lin Y, Tseng A, Abtin F, Suh RD, Oh S, Aberle DR, Winter LE, Wallace WD, Elashoff D, Garon EB, Sharma S, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. Barcelona, Spain. Journal of Thoracic Oncology. 2019;14:S978. DOI: 10.1016/j.jtho.2019.08.2147.

61. Oezkan F, He K, Owen DH, Pietrzak M, Cho JH, Kitzler R, Pearson R, Rusch VW, Chaft JE, Suh R, Blasberg JD, Reckamp KL, Raz DJ, Kneuertz PJ, Fiorillo L, Garon E, Nicholas A, Johnson A, Schulze K, Phan S, Bunn PA Jr., Kwiatkowski DJ, Johnson BE, Kris MG, Wistuba II, Lee JM, Lozanski G, Carbone DP.
Neoadjuvant atezolizumab in resectable NSCLC: Immunophenotyping results from the efficacy interim analysis of the multicenter LCMC3 trial.
World Conference on Lung Cancer (WCLC), IASLC. Barcelona, Spain. 2019.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

62. Lee JM, Chaft J, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura E, Raz DJ, Reckamp K, Merritt RE, Owen D, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Johnson A, Phan S, Schulze K, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Carbone DP, Rusch VW.
Surgical outcomes of a multicenter Phase II trial of neoadjuvant atezolizumab in resectable stages IB–IIIB NSCLC: Update on LCMC3 clinical trial.
World Conference on Lung Cancer (WCLC), IASLC. Barcelona, Spain. Journal of Thoracic Oncology. October 2019;14(10 Suppl):S744. DOI: 10.1016/j.jtho.2019.08.1593.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

63. Kwiatkowski DJ, Rusch V, Chaft J, Johnson B, Nicholas A, Wistuba I, Merritt R, Lee JM, Bunn P, Tang Y, Phan S, Waqar SN, Patterson A, Haura E, Toloza EM, Reckamp KL, Raz D, Schulze K, Johnson A, Carbone DP.
Neoadjuvant atezolizumab in resectable non–small cell lung cancer (NSCLC): Interim analysis and biomarker data from the multicenter LCMC3 study.
ASCO Annual Meeting. Journal of Clinical Oncology. 2019;37(Suppl):Abstract 8503.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

64. Liu B, Garon E, Lisberg A, Salehi-Rad R, Lee JM, Tran L, Krysan K, Li R, Lim R, Paul M, Lin Y, Jing Z, Abtin F, Suh R, Oh S, Aberle D, Winter L, Wallace W, Elashoff D, Dubinett S.
A Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
AACR Annual Meeting 2019. Abstract CT226. DOI: 10.1158/1538-7445.SABCS18-CT226.

65. Liu B, Lisberg A, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Li R, Lim RJ, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft SJ, Oh S, Aberle D, Winter LE, Sharma S, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
Journal of Thoracic Oncology. 2020;15(Suppl 1):S23.

66. Lee JM, Garrido P, Kim ES, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T.
Randomized Phase II study of canakinumab or pembrolizumab alone or in combination as neoadjuvant therapy in resectable stage IB–IIIA NSCLC (CANOPY-N).
AACR Annual Meeting 2020, San Diego, CA.
Served as Surgical Chair, CANOPY-N Trial.

67. Paz-Ares L, Garon EB, Mok T, Ardizzoni A, Barlesi F, Cho BC, de Castro G, De Marchi P, Felip E, Goto Y, Greystoke A, Lu S, Lim DWT, Reck M, Solomon BJ, Spigel DR, Tan DSW, Thomas M, Yang JCH, Lee JM, Garrido P, Kim E, Johnson BE.
CANOPY program clinical trials: Canakinumab (Cana) in patients with non–small cell lung cancer (NSCLC).
AACR Annual Meeting 2020, San Diego, CA.
Served as Surgical Chair, CANOPY-N Trial.

68. Garrido-Lopez P, Mok T, Kim E, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Lee JM.
CANOPY-N: Phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in resectable stage IB–IIIA NSCLC.
European Lung Cancer Congress (ELCC) 2020, Geneva, Switzerland.
Served as Surgical Chair, CANOPY-N Trial.

69. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Li R, Lin Y, Tseng A, Abtin F, Suh RD, Oh S, Aberle DR, Winter LE, Wallace WD, Elashoff D, Garon EB, Sharma S, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. Virtual, Singapore. 2020.

70. Lee JM, Wistuba II, Ngiam C, Yu W, Schulze K, Rocha M, Bara I, Carbone DP, Johnson BE, Kwiatkowski DJ, Rusch V, Chaft J.
Phase II study of TKIs as neoadjuvant therapy in resectable stage I–III NSCLC with ALK, ROS1, NTRK, or BRAFV600 alterations (NAUTIKA1).
World Conference on Lung Cancer (WCLC), IASLC. Virtual, Singapore. 2020.
Served as Surgical Chair, NAUTIKA Trial.

71. Lee JM, Garrido P, Kim ES, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T.
CANOPY-N: Neoadjuvant canakinumab or pembrolizumab in resectable NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. Virtual, Singapore. 2020.
Served as Surgical Chair, CANOPY-N Trial.

72. Lee JM, Chaft J, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura E, Raz DJ, Reckamp K, Merritt RE, Owen D, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Phan S, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Carbone DP, Rusch VW.
Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis.
World Conference on Lung Cancer (WCLC), IASLC. Virtual, Singapore. 2020.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

73. Mok T, Garrido P, Kim ES, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Lee JM.
Randomized Phase II study of canakinumab or pembrolizumab alone or in combination as neoadjuvant therapy in resectable stage IB–IIIA NSCLC (CANOPY-N).
ASCO Annual Meeting 2020, Chicago, IL.
Served as Surgical Chair, CANOPY-N Trial.

74. Garrido-Lopez P, Mok T, Kim E, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Lee JM.
CANOPY-N: Phase II study of canakinumab or pembrolizumab as neoadjuvant monotherapy or combination therapy in resectable NSCLC.
European Lung Cancer Congress (ELCC) 2020.
Served as Surgical Chair, CANOPY-N Trial.

75. Lee JM, Garrido P, Kim ES, Arslan C, Pujol JL, Tsuboi M, Dong T, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T.
Canakinumab or pembrolizumab as monotherapy or combination neoadjuvant therapy in resectable NSCLC: CANOPY-N trial.
AATS International Thoracic Surgical Oncology Summit (ITSOS) 2020.
Served as Surgical Chair, CANOPY-N Trial.

76. Lee JM, Garrido P, Kim ES, Arslan C, Pujol JL, Tsuboi M, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T.
Canakinumab or pembrolizumab as neoadjuvant therapy in resectable NSCLC (CANOPY-N trial).
IASLC North America Conference on Lung Cancer (NACLC) 2020.
Served as Surgical Chair, CANOPY-N Trial.

77. Kozan P, Lee JM, Wang HL, Gluckman C, Onyshchenko M, Muthusamy VR, Issa D.
Regression of Barrett’s esophagus after neoadjuvant therapy for esophageal adenocarcinoma.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2020.

78. Lee JM, Garrido P, Kim ES, Arslan C, Pujol JL, Song Y, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Mok T.
CANOPY-N trial: Neoadjuvant canakinumab or pembrolizumab in resectable NSCLC.
AACR Annual Meeting 2021. Cancer Research. 2021;81(13 Suppl):Abstract CT237.
Served as Surgical Chair, CANOPY-N Trial.

79. Lee JM, Mok T, Garrido P, Arslan C, Tsuboi M, Dong T, Blin C, Rodrik-Outmezguine V, Mookerjee B, Passos V, Pujol JL.
Neoadjuvant canakinumab or pembrolizumab in resectable NSCLC: CANOPY-N trial.
American Thoracic Society (ATS) Annual Meeting 2021. Am J Respir Crit Care Med. 2021;203:A4803.
Served as Surgical Chair, CANOPY-N Trial.

80. Lee JM, Pujol JL, Garrido P, Kim ES, Tsuboi M, Bitton RC, Duan J, Blin C, Savchenko A, Mok T.
CANOPY–N: Neoadjuvant canakinumab or pembrolizumab in resectable NSCLC.
AACR–NCI–EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021.
Served as Surgical Chair, CANOPY-N Trial.

81. Kelly K, Awad MM, Saliba T, Caro N, Inserra B, Banerjee H, Lee JM.
Neoadjuvant and adjuvant capmatinib in resectable NSCLC with MET exon 14 skipping mutation or high MET amplification: GEOMETRY–N trial.
AACR–NCI–EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. DOI: 10.1158/1535-7163.TARG-21-LBA046.
Served as Surgical Chair, GEOMETRY-N Trial.

82. Lee JM, Wang R, Abbass IM, Sheinson D, Kent M, Johnson A, Lee JS.
Real-world treatment patterns in stages IA–IIIB NSCLC.
ASCO Annual Meeting 2021.

83. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Lim R, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft S, Fishbein G, Kaul A, Kahlon K, Ashouri S, Goldman J, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells combined with pembrolizumab for advanced NSCLC.
ASCO Annual Meeting 2021. Journal of Clinical Oncology. 2021;39(15 Suppl):TPS9135.

84. Dacic S, Travis WD, Giltnane J, Abel J, Kos F, Hilz S, Hennek S, Fujimoto J, Sholl L, Khalil F, Ritter J, D’Apuzzo M, Lee JM, Rusch V, Carbone D, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II.
AI-powered pathologic response assessment after neoadjuvant atezolizumab in resected lung cancers: LCMC3 results.
ASCO Annual Meeting 2021. Journal of Clinical Oncology. 2021;39(15 Suppl):106. DOI: 10.1200/JCO.2021.39.15_suppl.106.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

85. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran L, Kostyantyn K, Lim R, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft S, Fishbein G, Kaul A, Kahlon K, Ashouri S, Goldman J, Elashoff D, Garon E, Dubinett S.
Phase I trial of in situ vaccination with CCL21-modified dendritic cells combined with pembrolizumab for advanced NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. Virtual, 2021.

86. Oezkan F, Seweryn M, Pietrzak M, Byun WY, Owen DH, Schulze K, Nicholas A, Hilz S, Grindheim J, Johnson A, Kwiatkowski DJ, Wistuba II, Johnson BE, Kris MG, Rusch VW, Lee JM, Lozanski G, Carbone DP.
LCMC3: Immune cell subtypes and nodal status predict pathologic regression after neoadjuvant atezolizumab in resectable NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. Virtual, 2021.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

87. Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS.
Real-world adjuvant treatment patterns and survival outcomes in early NSCLC patients in the United States.
European Society for Medical Oncology (ESMO) Congress 2021.

88. Lee P, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon E, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG Jr., Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow A.
iSABR: Safety and efficacy of SABR combined with durvalumab in early-stage medically inoperable NSCLC.
ASTRO Annual Meeting 2022.

89. Tian S, Kozono D, Ohri N, Jolly S, Johnson BE, Chaft J, Toloza E, Ding B, Ngiam C, Schulze K, Bara I, Lee JM.
NAUTIKA1: Multicenter Phase II study with PD-L1+ cohort receiving atezolizumab with low-dose SBRT as neoadjuvant therapy for stage IB–III NSCLC.
ASTRO Annual Meeting 2022.

90. Kris MG, Grindheim JM, Chaft JE, Lee JM, Johnson BE, Rusch VW, Bunn PA Jr., Pass HI, Shum E, Carlisle J, Weyant M, Nicholas A, Johnson A, Shames D, Wistuba II, Carbone DP, Schulze K, Kwiatkowski DJ.
Dynamic circulating tumor DNA response to neoadjuvant atezolizumab and surgery and association with outcomes in NSCLC.
ESMO Immuno-Oncology Congress 2022.
Served as Thoracic Surgery Co-Chair, LCMC3 Trial.

91. Lee JM, Wang R, Johnson A, Ogale S, Kent M, Lee JS.
Economic burden of recurrence among resected early-stage NSCLC Medicare patients.
ISPOR Annual Meeting 2022.

92. Zhou N, Deng J, Faltermeier C, Revels S, Toste P, Cameron R, Lee JM, Yanagawa J.
The majority of patients with resectable incidental lung cancers are ineligible for lung cancer screening.
Western Thoracic Surgical Association (WTSA) Annual Meeting 2022.

93. Lee JM, Awad MM, Saliba T, Caro N, Banerjee H, Kelly K.
Neoadjuvant and adjuvant capmatinib in resectable NSCLC with MET exon 14 skipping mutation or high MET amplification: GEOMETRY–N trial.
AACR Annual Meeting 2022.

94. Kidane B, Bott M, Spicer J, Backhus L, Chaft J, Chudgar N, Colson Y, D’Amico T, David E, Lee JM, Najmeh S, Sepesi B, Shu C, Yang J, Stiles B, Swanson S.
Staging and multidisciplinary management of early-stage NSCLC: AATS expert panel consensus.
AATS 102nd Annual Meeting 2022.

95. Lee JM, Vallieres E, Ding B, Johnson A, Bhagwakar J, Rashidi S, Zhu Q, Gitlitz B, Weksler B, Costas K, Altorki N.
Safety and tolerability of adjuvant atezolizumab following chemotherapy in stage II–IIIA NSCLC patients after pneumonectomy or bilobectomy: IMpower010 trial results.
AATS 102nd Annual Meeting 2022.

96. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Lim R, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft S, Oh S, Fishbein G, O’Higgins C, Ashouri S, Goldman JW, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
ASCO Annual Meeting 2022.

97. Lee JM, Awad MM, Saliba TR, Caro N, Banerjee H, Kelly K.
Neoadjuvant and adjuvant capmatinib in resectable NSCLC with MET exon 14 skipping mutation or high MET amplification: GEOMETRY–N trial.
ASCO Annual Meeting 2022.

98. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Lim R, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft S, Oh S, Fishbein GA, O’Higgins C, Greenwald D, Goldman JW, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2022.

99. Oezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen DH, Nicholas A, Yadav M, Nagakar D, de Almeida P, Ebert P, Osbourne E, Johnson A, Lee JM, Bunn P, Johnson BE, Chaft J, Kris MG, Rusch VW, Schulze K, Kwiatkowski DJ, Wistuba II, Carbone DP.
T-cell dynamics in response to neoadjuvant atezolizumab in early NSCLC by antigen response and TCR sequencing.
World Conference on Lung Cancer (WCLC), IASLC. 2022.

100. Lee JM, Sepesi B, Toloza EM, Lin J, Pass HI, Johnson BE, Heymach JV, Johnson ML, Ding B, Schulze K, Zhu Q, Ngiam C, Brandao E, Bara I, Chaft J.
Phase II NAUTIKA1 study of targeted therapies in stage II–III NSCLC: Preliminary data of neoadjuvant alectinib for ALK⁺ NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2022.

101. Scott S, Hu C, Prophet E, Smith K, Anagnostou V, Lee JM, Spicer J, Illei P, Taube J, Ettinger D, Feliciano J, Hann C, Lam V, Levy B, Murray J, Brahmer J, Forde P, Marrone K.
Phase II trial of neoadjuvant KRAS G12C–directed therapy with adagrasib (MRTX849) with or without nivolumab in resectable non–small cell lung cancer (Neo-KAN).
World Conference on Lung Cancer (WCLC), IASLC. 2022.

102. Lee JM, Vallieres E, Ding B, Johnson A, Bhagwakar J, Rashidi S, Zhu Q, Gitlitz B, Weksler B, Coastas K, Altorki N.
Safety and tolerability of adjuvant atezolizumab following chemotherapy in stage II–IIIA NSCLC after pneumonectomy or bilobectomy: IMpower010 trial.
AATS International Thoracic Surgical Oncology Summit (ITSOS) 2022.

103. Lee JM, Kozono D, Ohri N, Jolly S, Johnson BE, Chaft J, Toloza E, Ding B, Ngiam C, Schulze K, Bara I, Tian S.
NAUTIKA1: Phase II study of neoadjuvant atezolizumab with low-dose stereotactic body radiation therapy in PD-L1+ resectable stage IB–III NSCLC.
AATS International Thoracic Surgical Oncology Summit (ITSOS) 2022.

104. Zhou C, Kenmotsu H, Lee JM, Novello S, Altorki N, Felip E, Vallieres E, Tao M, Liu Y, Johnson A, Bhagwakar J, Huang M, Zhu Q, Ding B, Zhou W, Das Thakur M, Bennett E, McNally V, Gitlitz B, Wakelee H.
IMpower010: Efficacy and safety of adjuvant atezolizumab in the Asian subpopulation, and efficacy by PD-L1 expression and ctDNA status in stage II–IIIA NSCLC.
Chinese Society of Clinical Oncology (CSCO) 2022.

105. Lisberg A, Liu B, Salehi-Rad R, Lee JM, Tran LM, Krysan K, Lim R, Dumitras C, Jing Z, Abtin F, Suh RD, Genshaft S, Oh S, Fishbein G, O’Higgins C, Ashouri S, Goldman JW, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells combined with pembrolizumab for advanced NSCLC.
European Society for Medical Oncology (ESMO) Congress 2022.

106. Mok TSK, Tsuboi M, Lee JM, Kim E, Pujol JL, Leonov O, Zhang J, Duan J, Lobetti-Bodoni C, Brase JC, Savchenko A, Garrido Lopez P.
CANOPY-N: Phase II study of canakinumab or pembrolizumab, alone or in combination, as neoadjuvant therapy in resectable stage IB–IIIA NSCLC.
ESMO Congress 2022.

107. Lee JM, Meyer CS, To TM, Lin CW, Wang S, Kent M, Johnson A, Lee JS.
Lymph node non-examination in early-stage NSCLC is associated with wedge resections and underuse of adjuvant chemotherapy.
ESMO Congress 2022.

108. Sepesi B, Jones DR, Meyers BF, Chaft JE, Sholl LM, Shyr Y, Kelly K, Lin J, Bunn PA, Minna JD, Rusch VW, Wistuba II, Kwiatkowski DJ, Carbone DP, Berry LD, Lee JM, Tolba K, Kris MG.
LCMC LEADER (LCMC4) screening trial: Evaluation of actionable drivers in early-stage lung cancer.
ASCO Annual Meeting 2022.

109. Lee JM, To TM, Lin CW, Wang S, Johnson A, Lee JS.
Association of lymph node examination during resection with overall survival and healthcare costs in early-stage NSCLC.
ASCO Annual Meeting 2023.

110. Presley CJ, Owen DH, Nicholas A, Hilz S, Oezkan F, Chaft JE, Toloza EM, Haura EB, Patterson A, Waqar SN, Bunn P, Johnson BE, Kris MG, Lee JM, Kwiatkowski DJ, Wistuba II, Schulze K, Johnson A, Rusch VW, Carbone DP.
Outcomes by age in neoadjuvant atezolizumab treatment for resectable NSCLC: Subset analysis of the Phase II LCMC3 study.
ASCO Annual Meeting 2023.

111. Carbone DP, Waqar SN, Chaft JE, Kris MG, Johnson BE, Lee JM, Wistuba II, Kwiatkowski DJ, Bunn PA, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang AC, Nicholas A, Rusch VW.
Updated survival, efficacy, and safety of adjuvant atezolizumab after neoadjuvant atezo in the Phase II LCMC3 study.
European Lung Cancer Congress (ELCC) 2023.

112. Carbone DP, Waqar SN, Chaft JE, Kris MG, Johnson BE, Lee JM, Wistuba II, Kwiatkowski DJ, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp KL, Chiang AC, Nicholas A, Rusch VW.
Efficacy and safety of adjuvant atezolizumab from the Phase II LCMC3 study.
AACR Annual Meeting 2023.

113. Carbone DP, Waqar SN, Chaft JE, Kris MG, Johnson BE, Lee JM, Wistuba II, Kwiatkowski DJ, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp KL, Chiang AC, Nicholas A, Rusch VW.
Updated survival, efficacy, and safety of adjuvant atezolizumab after neoadjuvant atezo in the Phase II LCMC3 study.
European Lung Cancer Congress (ELCC) 2023.

114. Presley CJ, Owen DH, Nicholas A, Hilz S, Oezkan F, Chaft JE, Toloza EM, Haura EB, Patterson A, Waqar SN, Bunn P, Johnson BE, Kris MG, Lee JM, Kwiatkowski DJ, Wistuba II, Schulze K, Johnson A, Rusch VW, Carbone DP.
Outcomes by age with neoadjuvant atezolizumab for resectable NSCLC: Phase II LCMC3 study.
World Conference on Lung Cancer (WCLC), IASLC. 2023.

115. Lee JM, Toloza EM, Pass HI, Johnson BE, Heymach JV, Sholl LM, Saqi A, Travis WD, Wistuba I, Lin J, Kris MG, Spira AI, Shu CA, Saito S, Ding B, Schulze K, Zhu Q, Ngiam C, Bara I, Chaft JE.
NAUTIKA1 study: Preliminary efficacy and safety with neoadjuvant alectinib in stage IB–III ALK⁺ NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2023.

116. Lee JM, Schulze K, Nedzesky J, Ng C, Ogale S, Johnson A, Hasan H, Secrest MH, Cohen AB, Castellanos E, Estola E, Estevez M, Lee JS.
Real-world biomarker testing and treatment patterns identified using machine learning in early NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2023.

117. Lee JM, Ogale S, Johnson A, Patel A, Albarmawi H, Lee JS.
Real-world treatment patterns among resected NSCLC patients receiving adjuvant atezolizumab.
North America Conference on Lung Cancer (NACLC) 2023.

118. Spicer JD, Nair SM, Khattack A, Lee JM, Brown M, Meehan RS, Shariati N, Chaft JE.
INTerpath-002: Phase III study design of individualized neoantigen therapy (V940, mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage NSCLC.
AACR Annual Meeting 2024.

119. Merritt RE, Patterson GA, Toloza EM, Lee JM, Raz DJ, Baciewicz F, Weyant M, Molena D, Isbell J, Kim J, Pass HI, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Bara I, Gasior G, Schulze K, Brandao E, Kneuertz PJ, Detterbeck F, Kozower B, Fontaine JP, Park B, McNamee CJ, Blasberg JD, Finley DJ, Nicholas A, Johnson A, Carbone DP, Rusch VW.
Clinical utility of SUVmax on preoperative PET-CT in NSCLC treated with neoadjuvant atezolizumab: Phase II LCMC3 study.
AATS Annual Meeting 2024.

120. Lee JM, Spicer JD, Nair SM, Khattack A, Brown M, Meehan RS, Shariati N, Deng X, Samkari A, Chaft JE.
INTerpath-002: Phase III study of individualized neoantigen therapy (V940, mRNA-4157) plus pembrolizumab vs placebo in resected early-stage NSCLC.
ASCO Annual Meeting 2024.

121. Chaft JE, Swanson S, Ripley T, Tsukada H, Lin J, Kaifi J, Baik C, Lee JM, Bunn P, Tambaoan CF, Huang RSP, Jones D, Kris MG.
LCMC4 (LEADER) screening trial: Preliminary results on actionable drivers in early-stage lung cancer.
ASCO Annual Meeting 2024.

122. Merritt RE, Patterson GA, Toloza EM, Lee JM, Raz DJ, Baciewicz F, Weyant M, Molena D, Isbell J, Kim J, Pass HI, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Bara I, Gasior G, Schulze K, Brandao E, Kneuertz PJ, Detterbeck F, Kozower B, Fontaine JP, Park B, McNamee CJ, Blasberg JD, Finley DJ, Nicholas A, Johnson A, Carbone DP, Rusch VW.
SUVmax on preoperative PET-CT as a predictive marker in resectable NSCLC treated with neoadjuvant atezolizumab: Phase II LCMC3.
World Conference on Lung Cancer (WCLC), IASLC. 2024.

123. Owen DH, Chaft JE, Haura EB, Toloza EM, Waqar SN, Patterson GA, Finley DJ, Blasberg J, Raz DJ, Salgia R, Lee JM, Bunn PA, Wistuba II, Kwiatkowski DJ, Hirsch FR, Gopalakrishnan A, Batra A, Brandao E, Grindheim JM, Nicholas A, Johnson A, Schulze K, Shum E, Nagasaka M, Gainor J, McNamee CJ, Johnson BE, Kris MG, Rusch VW, Carbone DP.
LCMC3: Long-term disease-free and overall survival and ctDNA correlation after neoadjuvant atezolizumab for NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2024.

124. Lee JM, Liao BC, Spicer J, Newsom-Davis T, Hui R, Xu Y, Song A, Samkari A, Hochmair M.
TroFuse-019: Phase III study of adjuvant pembrolizumab with or without Sac-TMT for resectable stage II–IIIB NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2024.

125. Cummings A, Rosettie K, Sussell J, El Moustaid F, Ogale S, Kochounian CN, Albarmawi H, Lee JM.
Estimating population-level recurrences avoided and cost savings with adjuvant alectinib for ALK⁺ NSCLC in the U.S.
ASCO Quality Care Symposium 2024.

126. Lisberg A, Liu B, Oh M, Dumitras C, Tsvetkova O, Salehi-Rad R, Tran LM, Krysan K, Lim RJ, Shabihkhani M, Romero T, Jing Z, Abtin F, Suh RD, Genshaft S, Oh S, Fishbein G, Tong C, Chung A, Hernandez S, Chauv J, Ling-LeBuffe J, Winter L, Kivork C, Kelly K, Greenwald D, Kahlon K, Anand S, Ashouri S, Goldman J, Lee JM, Elashoff D, Garon EB, Dubinett SM.
Phase I trial of in situ vaccination with autologous CCL21 gene-modified dendritic cells combined with pembrolizumab for metastatic NSCLC.
Society for Immunotherapy of Cancer (SITC) 2024.

127. Lee JM, Grindheim JM, Chaft JE, Johnson BE, Wistuba II, Bunn PA, Kwiatkowski DJ, Toloza EM, Raz DJ, D’Souza DM, Finley DJ, Downey RJ, Brandao E, Nicholas A, Johnson A, Schulze K, Kris MG, Carbone DP, Rusch VW.
LCMC3: Survival impact of ctDNA status after neoadjuvant atezolizumab in relation to response, resection status, and adjuvant therapy.
AATS International Thoracic Surgical Oncology Summit (ITSOS) 2024.

128. Lee JM, Liao BC, Spicer J, Newsom-Davis T, Hui R, Xu Y, Song A, Samkari A, Hochmair M.
TroFuse-019: Adjuvant pembrolizumab with or without sacituzumab tirumotecan for resectable stage II–IIIB NSCLC.
Chinese Society of Clinical Oncology (CSCO) 2024.

129. Lee P, Goldman J, Garon E, Luterstein E, Neilsen B, Lee JM, Felix C, Cao M, Tenn S, Low D, Kupelian P, Steinberg M, Wu T.
Accelerated hypofractionated chemoradiation followed by SABR boost for locally advanced unresectable NSCLC: Final results.
ASTRO Annual Meeting 2024.

130. Lee JM, Simmons D, Mulrooney T, Snider J, Kovacevic LN, Schwed K, Juloori A.
Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in stage II/III NSCLC in the U.S.
ASCO Annual Meeting 2025.

131. Dragnev KH, Erman M, Bria E, Lee JM, Manschot C, Thompson JC, Samkari A, Spicer J.
KEYMAKER-U01E: Phase II umbrella study of investigational agents ± chemotherapy plus pembrolizumab for resectable stage II–IIIB NSCLC.
ASCO Annual Meeting 2025.

132. Lee JM, Rhead B, Garon E, Goldman J, Velez M, Gower A, Lisberg A, Boutros PC, Dubinett SM, Williams E, Hegarty-Traverso C, Fragkogianni S, Mercer J, Cummings A.
ImmunoDriver-1: Driver alterations and immune implications in early and metastatic NSCLC.
ASCO Annual Meeting 2025.

133. Nadal E, Chaft J, Garassino M, Gray J, Lee S, Lee JM, Mazieres J, Neal J, Negrao M, Popat S, Senan S, Tsuboi M, Wu Y, Zhao X, Liu H, Zhang Y, Thomas M.
SUNRAY-02: Phase III study of olomorasib plus standard immunotherapy for KRAS G12C–mutant NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2025.

134. Lee JM, Negrao MV, Cummings A, Shum E, Patil T, Lin J, Shu CA, Saltos A, Florez N, Blakely CM, Sholl L, Saqi A, Ding B, Zhu Q, Schulze K, Grindheim J, Bara I, Ngiam C, Chaft JE.
NAUTIKA1: Clinical outcomes and pathologic regression with neoadjuvant alectinib in resectable stage IB–IIIB ALK⁺ NSCLC.
World Conference on Lung Cancer (WCLC), IASLC. 2025.

135. Lee JM, Rhead B, Garon E, Goldman J, Velez M, Gower A, Lisberg A, Boutros PC, Dubinett SM, Williams E, Jariwala U, Hegarty-Traverso C, Fragkogianni S, Thompson M, Mercer J, Cummings A.
ImmunoDriver-2: CD8 T-cell and PD-L1 levels correlate with survival in ICI-treated NSCLC.
European Society for Medical Oncology (ESMO) Congress 2025.

136. Lee JM, Rai P, Pathan M, Kao YH, Thompson J, Hu X, Arunachalam A, Samkari A, Aggarwal C.
Primary treatment patterns in stage I–IIIB NSCLC: Analysis of U.S. electronic health records.
North America Conference on Lung Cancer (NACLC) 2025.

Office Address:
UCLA Division of Thoracic Surgery
Box 957313, Room 64-128 CHS
10833 Le Conte Avenue, Los Angeles, California 90095-7313

Telephone: (310) 794-7333
Facsimile: (310) 794-7335
Email: [email protected]